Global Liquid Biopsy Market: By Product & Service, By Circulating Biomarker, By Clinical Application, By Technology, By Application, By Sample Type, By End User, By Region & Segmental Insights Trends and Forecast, 2024 – 2034

  • Industry: Healthcare
  • Report ID: TNR-110-1144
  • Number of Pages: 420
  • Table/Charts : Yes
  • June, 2024
  • Base Year : 2024
  • No. of Companies : 10+
  • No. of Countries : 29
  • Views : 10032
  • Covid Impact Covered: Yes
  • War Impact Covered: Yes
  • Formats : PDF, Excel, PPT

Liquid biopsy is a revolutionary diagnostic technique that enables the non-invasive detection and analysis of biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other molecules present in bodily fluids like blood, urine, or cerebrospinal fluid. Unlike traditional tissue biopsies, which involve invasive procedures to obtain tissue samples from tumors, liquid biopsy offers a minimally invasive approach for monitoring cancer progression, treatment response, and the emergence of resistance mutations. This technique holds immense promise in oncology by providing clinicians with real-time and comprehensive information about a patient’s cancer status, including genetic mutations, tumor heterogeneity, and the potential for metastasis. Liquid biopsy also facilitates the identification of actionable genetic alterations, guiding the selection of targeted therapies and enabling personalized treatment strategies tailored to individual patients. Moreover, liquid biopsy holds potential beyond oncology, with applications in infectious disease monitoring, prenatal screening, and transplant rejection surveillance, underscoring its versatility and significance in modern medicine.

The demand for liquid biopsy is propelled by several key factors reshaping the landscape of cancer diagnosis and treatment. One primary demand driver is the increasing recognition of the limitations and challenges associated with traditional tissue biopsies, including invasiveness, sampling bias, and the inability to capture tumor heterogeneity. Liquid biopsy offers a non-invasive alternative that allows for repeated sampling and real-time monitoring of tumor dynamics, providing valuable insights into disease progression and treatment response. Additionally, the growing emphasis on precision medicine and personalized oncology drives the demand for liquid biopsy tests, as they enable the identification of specific genetic mutations and molecular alterations guiding targeted therapy selection. The rise in cancer incidence globally further amplifies the need for more accessible and efficient diagnostic tools capable of detecting cancer at early stages when treatment is most effective. Moreover, advancements in technology, such as Next-Generation Sequencing (NGS) and digital PCR, enhance the sensitivity and specificity of liquid biopsy assays, expanding their utility in clinical practice and fuelling market demand. In terms of revenue, the global liquid biopsy market was worth US$ 6.5 Bn in 2023, anticipated to witness CAGR of 12.2% during 2024 – 2034.

Global Liquid Biopsy Market Dynamics

Rising Cancer Incidence: The increasing prevalence of cancer globally serves as a primary driver for the liquid biopsy market, as these tests offer non-invasive methods for early detection, monitoring, and treatment response assessment. Increased patient awareness of liquid biopsy benefits, such as reduced invasiveness and potential for early disease detection, contributes to market growth by driving demand for these tests.

Technological Advancements: Ongoing advancements in sequencing technologies, such as Next-Generation Sequencing (NGS) and digital PCR, enhance the sensitivity and specificity of liquid biopsy assays, expanding their utility in clinical settings. Liquid biopsy applications are expanding beyond oncology to include infectious disease monitoring, prenatal screening, and transplant rejection monitoring, broadening the market potential.

Growing Adoption of Precision Medicine: The shift towards personalized treatment approaches drives demand for liquid biopsy tests, as they enable the identification of specific genetic mutations and molecular alterations guiding targeted therapy selection. Growing investments in research and development initiatives fuel innovation in liquid biopsy technologies, leading to the development of novel assays and biomarkers.

Cancer Application Segment has Garnered Major Market Share in the Global Liquid Biopsy Market During the Forecast Period (2024 – 2034).

Cancer applications of liquid biopsy represent a significant demand driver in the medical field, spurred by the need for non-invasive and real-time monitoring of cancer progression and treatment response. Liquid biopsies offer a minimally invasive alternative to traditional tissue biopsies, enabling the detection and analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers present in bodily fluids like blood or urine. This approach is particularly valuable for patients with advanced or metastatic cancer, where obtaining tissue samples may be challenging or risky. Additionally, liquid biopsy facilitates the identification of actionable genetic mutations and allows for the early detection of treatment resistance, guiding more personalized and effective therapeutic interventions. The growing prevalence of cancer globally, coupled with advancements in technology and the increasing adoption of precision medicine approaches, fuels the demand for liquid biopsy-based cancer applications as essential tools in oncology research and clinical practice.

By Technology Multi-Gene Parallel Analysis using NGS Segment had the Highest Share in the Global Liquid Biopsy Market in 2023.

The integration of Multi-gene Parallel Analysis using Next-Generation Sequencing (NGS) technology into liquid biopsy methods emerges as a significant demand driver in the healthcare sector. This advanced approach enables the simultaneous analysis of multiple genes from circulating tumor DNA (ctDNA) or other biomarkers present in bodily fluids, revolutionizing cancer diagnostics and treatment monitoring. The demand for such precision medicine tools stems from the increasing recognition of the heterogeneity of cancer and the need for comprehensive molecular profiling to guide targeted therapies effectively. In addition, the rise in cancer incidence rates globally, coupled with the growing emphasis on early detection and personalized treatment strategies, further propels the adoption of multi-gene parallel analysis using NGS in liquid biopsies. Moreover, the continuous evolution and refinement of NGS technologies, alongside decreasing costs and improved accessibility, contribute to the expanding demand for these innovative diagnostic approaches, reshaping the landscape of cancer care.

By Region, North America Dominated the Global Liquid Biopsy Market in 2023.

In North America, the adoption of liquid biopsy techniques serves as a significant demand driver in the healthcare landscape. Liquid biopsy, a minimally invasive diagnostic method that analyses biomarkers circulating in bodily fluids like blood, presents a promising alternative to traditional tissue biopsies for detecting and monitoring diseases such as cancer. The region’s aging population, coupled with the increasing prevalence of cancer and other chronic diseases, amplifies the demand for more accessible and timely diagnostic tools. Liquid biopsy offers several advantages, including the ability to track disease progression, monitor treatment efficacy, and detect early-stage cancers, thereby facilitating more personalized and targeted therapies. Furthermore, the strong research and development infrastructure in North America, along with favorable regulatory policies promoting innovation in healthcare, fosters the adoption of liquid biopsy technologies, positioning it as a vital component in the fight against cancer and other diseases in the region.

Competitive Landscape: Global Liquid Biopsy Market:

  • Biocept Inc.
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health
  • Illumina, Inc.
  • Johnson & Johnson
  • Laboratory Corporation of America Holdings
  • MDxHealth SA
  • QIAGEN N.V
  • Thermo Fisher Scientific Inc.
  • Other Industry Participants

Global Liquid Biopsy Market Scope

Report Specifications Details
Market Revenue in 2023 US$ 6.5 Bn
Market Size Forecast by 2034 US$ 23.1 Bn
Growth Rate (CAGR) 12.2%
Historic Data 2016 – 2022
Base Year for Estimation 2023
Forecast Period 2024 – 2034
Report Inclusions Market Size & Estimates, Market Dynamics, Competitive Scenario, Trends, Growth Factors, Market Determinants, Key Investment Segmentation, Product/Service/Solutions Benchmarking
Segments Covered By Product & Service, By Circulating Biomarker, By Clinical Application, By Technology, By Application, By Sample Type, By End User, By Region
Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Countries Covered U.S., Canada, Mexico, Rest of North America,  France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe,  China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific,  Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,  Brazil, Argentina, Rest of Latin America
Key Players Biocept Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd., Guardant Health, Illumina, Inc., Johnson & Johnson, Laboratory Corporation of America Holdings, MDxHealth SA, QIAGEN N.V, Thermo Fisher Scientific Inc.
Customization Scope Customization allows for the inclusion/modification of content pertaining to geographical regions, countries, and specific market segments.
Pricing & Procurement Options Explore purchase options tailored to your specific research requirements
Contact Details Consult With Our Expert

Japan (Toll-Free):  +81 663-386-8111

South Korea (Toll-Free):  +82-808- 703-126

Saudi Arabia (Toll-Free):  +966 800-850-1643

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

E-mail:  askanexpert@thenicheresearch.com

 

Global Liquid Biopsy Market

By Product & Service

  • Assay Kits
  • Instruments
  • Services

By Circulating Biomarker

  • Circulating Tumor Cells
  • Circulating Tumor DNA
  • Cell-free DNA
  • Extracellular Vesicles
  • Other Circulating Biomarkers

By Clinical Application

  • Early Cancer Screening
  • Therapy Selection
  • Treatment Monitoring
  • Recurrence Monitoring

By Technology

  • Multi-gene Parallel Analysis using NGS
  • Single-gene Analysis using PCR

By Application

  • Cancer Applications
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Melanoma
    • Other Cancers
  • Non-cancer Applications
    • Non-Invasive Prenatal Testing
    • Organ Transplantation
    • Infectious Disease Testing

By Sample Type

  • Blood Sample
  • Other Sample Types

By End User

  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Academic & Research Centers
  • Other End Users

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

Report Layout:

Table of Contents

.

1.Market Scope
1.1.Market Segmentation
1.2.Years Considered
1.2.1.Historic Years: 2016 – 2022
1.2.2.Base Year: 2023
1.2.3.Forecast Years: 2024 – 2034
2.Key Target Audiences
3.Research Methodology
3.1.Primary Research
3.1.1.Research Questionnaire
3.1.2.Global Percentage Breakdown
3.1.3.Primary Interviews: Key Opinion Leaders (KOLs)
3.2.Secondary Research
3.2.1.Paid Databases
3.2.2.Secondary Sources
3.3.Market Size Estimates
3.3.1.Top-Down Approach
3.3.2.Bottom-Up Approach
3.4.Data Triangulation Methodology
3.5.Research Assumptions
4.Recommendations and Insights from TNR’s Perspective**
5.Holistic Overview of Liquid Biopsy Market
6.Market Synopsis: Liquid Biopsy Market
7.Liquid Biopsy Market Analysis: Qualitative Perspective
7.1.Introduction
7.1.1.Product Definition
7.1.2.Industry Development
7.2.Market Dynamics
7.2.1.Drivers
7.2.2.Restraints
7.2.3.Opportunities
7.2.4.Challenges
7.3.Trends in Liquid Biopsy Market
7.4.Market Determinants Radar Chart
7.5.Macro-Economic and Micro-Economic Indicators: Liquid Biopsy Market
7.6.Industry Gross Margin Overview
7.7.Porter’s Five Force Analysis
7.8.Impact of Covid-19 on Liquid Biopsy Market
7.9.PESTEL Analysis
7.10.Value Chain Analysis
7.11.Pricing Analysis, By Region (2023)
7.11.1.North America
7.11.2.Europe
7.11.3.Asia Pacific
7.11.4.Middle East and Africa
7.11.5.Latin America
8.Global Liquid Biopsy Market Analysis and Forecasts, 2024 – 2034
8.1.Overview
8.1.1.Global Liquid Biopsy Market Revenue (US$ Mn)
8.2.Global Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
8.2.1.Assay Kits
8.2.1.1.Definition
8.2.1.2.Market Estimation and Penetration, 2016 – 2023
8.2.1.3.Market Forecast, 2024 – 2034
8.2.1.4.Compound Annual Growth Rate (CAGR)
8.2.1.5.Regional Bifurcation
8.2.1.5.1.North America
8.2.1.5.1.1.Market Estimation, 2016 – 2023
8.2.1.5.1.2.Market Forecast, 2024 – 2034
8.2.1.5.2.Europe
8.2.1.5.2.1.Market Estimation, 2016 – 2023
8.2.1.5.2.2.Market Forecast, 2024 – 2034
8.2.1.5.3.Asia Pacific
8.2.1.5.3.1.Market Estimation, 2016 – 2023
8.2.1.5.3.2.Market Forecast, 2024 – 2034
8.2.1.5.4.Middle East and Africa
8.2.1.5.4.1.Market Estimation, 2016 – 2023
8.2.1.5.4.2.Market Forecast, 2024 – 2034
8.2.1.5.5.Latin America
8.2.1.5.5.1.Market Estimation, 2016 – 2023
8.2.1.5.5.2.Market Forecast, 2024 – 2034
8.2.2.Instruments
8.2.2.1.Definition
8.2.2.2.Market Estimation and Penetration, 2016 – 2023
8.2.2.3.Market Forecast, 2024 – 2034
8.2.2.4.Compound Annual Growth Rate (CAGR)
8.2.2.5.Regional Bifurcation
8.2.2.5.1.North America
8.2.2.5.1.1.Market Estimation, 2016 – 2023
8.2.2.5.1.2.Market Forecast, 2024 – 2034
8.2.2.5.2.Europe
8.2.2.5.2.1.Market Estimation, 2016 – 2023
8.2.2.5.2.2.Market Forecast, 2024 – 2034
8.2.2.5.3.Asia Pacific
8.2.2.5.3.1.Market Estimation, 2016 – 2023
8.2.2.5.3.2.Market Forecast, 2024 – 2034
8.2.2.5.4.Middle East and Africa
8.2.2.5.4.1.Market Estimation, 2016 – 2023
8.2.2.5.4.2.Market Forecast, 2024 – 2034
8.2.2.5.5.Latin America
8.2.2.5.5.1.Market Estimation, 2016 – 2023
8.2.2.5.5.2.Market Forecast, 2024 – 2034
8.2.3.Services
8.2.3.1.Definition
8.2.3.2.Market Estimation and Penetration, 2016 – 2023
8.2.3.3.Market Forecast, 2024 – 2034
8.2.3.4.Compound Annual Growth Rate (CAGR)
8.2.3.5.Regional Bifurcation
8.2.3.5.1.North America
8.2.3.5.1.1.Market Estimation, 2016 – 2023
8.2.3.5.1.2.Market Forecast, 2024 – 2034
8.2.3.5.2.Europe
8.2.3.5.2.1.Market Estimation, 2016 – 2023
8.2.3.5.2.2.Market Forecast, 2024 – 2034
8.2.3.5.3.Asia Pacific
8.2.3.5.3.1.Market Estimation, 2016 – 2023
8.2.3.5.3.2.Market Forecast, 2024 – 2034
8.2.3.5.4.Middle East and Africa
8.2.3.5.4.1.Market Estimation, 2016 – 2023
8.2.3.5.4.2.Market Forecast, 2024 – 2034
8.2.3.5.5.Latin America
8.2.3.5.5.1.Market Estimation, 2016 – 2023
8.2.3.5.5.2.Market Forecast, 2024 – 2034
8.3.Key Segment for Channeling Investments
8.3.1.By Product and Service
9.Global Liquid Biopsy Market Analysis and Forecasts, 2024 – 2034
9.1.Overview
9.2.Global Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
9.2.1.Circulating Tumor Cells
9.2.1.1.Definition
9.2.1.2.Market Estimation and Penetration, 2016 – 2023
9.2.1.3.Market Forecast, 2024 – 2034
9.2.1.4.Compound Annual Growth Rate (CAGR)
9.2.1.5.Regional Bifurcation
9.2.1.5.1.North America
9.2.1.5.1.1.Market Estimation, 2016 – 2023
9.2.1.5.1.2.Market Forecast, 2024 – 2034
9.2.1.5.2.Europe
9.2.1.5.2.1.Market Estimation, 2016 – 2023
9.2.1.5.2.2.Market Forecast, 2024 – 2034
9.2.1.5.3.Asia Pacific
9.2.1.5.3.1.Market Estimation, 2016 – 2023
9.2.1.5.3.2.Market Forecast, 2024 – 2034
9.2.1.5.4.Middle East and Africa
9.2.1.5.4.1.Market Estimation, 2016 – 2023
9.2.1.5.4.2.Market Forecast, 2024 – 2034
9.2.1.5.5.Latin America
9.2.1.5.5.1.Market Estimation, 2016 – 2023
9.2.1.5.5.2.Market Forecast, 2024 – 2034
9.2.2.Circulating Tumor DNA
9.2.2.1.Definition
9.2.2.2.Market Estimation and Penetration, 2016 – 2023
9.2.2.3.Market Forecast, 2024 – 2034
9.2.2.4.Compound Annual Growth Rate (CAGR)
9.2.2.5.Regional Bifurcation
9.2.2.5.1.North America
9.2.2.5.1.1.Market Estimation, 2016 – 2023
9.2.2.5.1.2.Market Forecast, 2024 – 2034
9.2.2.5.2.Europe
9.2.2.5.2.1.Market Estimation, 2016 – 2023
9.2.2.5.2.2.Market Forecast, 2024 – 2034
9.2.2.5.3.Asia Pacific
9.2.2.5.3.1.Market Estimation, 2016 – 2023
9.2.2.5.3.2.Market Forecast, 2024 – 2034
9.2.2.5.4.Middle East and Africa
9.2.2.5.4.1.Market Estimation, 2016 – 2023
9.2.2.5.4.2.Market Forecast, 2024 – 2034
9.2.2.5.5.Latin America
9.2.2.5.5.1.Market Estimation, 2016 – 2023
9.2.2.5.5.2.Market Forecast, 2024 – 2034
9.2.3.Cell-free DNA
9.2.3.1.Definition
9.2.3.2.Market Estimation and Penetration, 2016 – 2023
9.2.3.3.Market Forecast, 2024 – 2034
9.2.3.4.Compound Annual Growth Rate (CAGR)
9.2.3.5.Regional Bifurcation
9.2.3.5.1.North America
9.2.3.5.1.1.Market Estimation, 2016 – 2023
9.2.3.5.1.2.Market Forecast, 2024 – 2034
9.2.3.5.2.Europe
9.2.3.5.2.1.Market Estimation, 2016 – 2023
9.2.3.5.2.2.Market Forecast, 2024 – 2034
9.2.3.5.3.Asia Pacific
9.2.3.5.3.1.Market Estimation, 2016 – 2023
9.2.3.5.3.2.Market Forecast, 2024 – 2034
9.2.3.5.4.Middle East and Africa
9.2.3.5.4.1.Market Estimation, 2016 – 2023
9.2.3.5.4.2.Market Forecast, 2024 – 2034
9.2.3.5.5.Latin America
9.2.3.5.5.1.Market Estimation, 2016 – 2023
9.2.3.5.5.2.Market Forecast, 2024 – 2034
9.2.4.Extracellular Vesicles
9.2.4.1.Definition
9.2.4.2.Market Estimation and Penetration, 2016 – 2023
9.2.4.3.Market Forecast, 2024 – 2034
9.2.4.4.Compound Annual Growth Rate (CAGR)
9.2.4.5.Regional Bifurcation
9.2.4.5.1.North America
9.2.4.5.1.1.Market Estimation, 2016 – 2023
9.2.4.5.1.2.Market Forecast, 2024 – 2034
9.2.4.5.2.Europe
9.2.4.5.2.1.Market Estimation, 2016 – 2023
9.2.4.5.2.2.Market Forecast, 2024 – 2034
9.2.4.5.3.Asia Pacific
9.2.4.5.3.1.Market Estimation, 2016 – 2023
9.2.4.5.3.2.Market Forecast, 2024 – 2034
9.2.4.5.4.Middle East and Africa
9.2.4.5.4.1.Market Estimation, 2016 – 2023
9.2.4.5.4.2.Market Forecast, 2024 – 2034
9.2.4.5.5.Latin America
9.2.4.5.5.1.Market Estimation, 2016 – 2023
9.2.4.5.5.2.Market Forecast, 2024 – 2034
9.2.5.Other Circulating Biomarkers
9.2.5.1.Definition
9.2.5.2.Market Estimation and Penetration, 2016 – 2023
9.2.5.3.Market Forecast, 2024 – 2034
9.2.5.4.Compound Annual Growth Rate (CAGR)
9.2.5.5.Regional Bifurcation
9.2.5.5.1.North America
9.2.5.5.1.1.Market Estimation, 2016 – 2023
9.2.5.5.1.2.Market Forecast, 2024 – 2034
9.2.5.5.2.Europe
9.2.5.5.2.1.Market Estimation, 2016 – 2023
9.2.5.5.2.2.Market Forecast, 2024 – 2034
9.2.5.5.3.Asia Pacific
9.2.5.5.3.1.Market Estimation, 2016 – 2023
9.2.5.5.3.2.Market Forecast, 2024 – 2034
9.2.5.5.4.Middle East and Africa
9.2.5.5.4.1.Market Estimation, 2016 – 2023
9.2.5.5.4.2.Market Forecast, 2024 – 2034
9.2.5.5.5.Latin America
9.2.5.5.5.1.Market Estimation, 2016 – 2023
9.2.5.5.5.2.Market Forecast, 2024 – 2034
9.3.Key Segment for Channeling Investments
9.3.1.By Circulating Biomarker
10.Global Liquid Biopsy Market Analysis and Forecasts, 2024 – 2034
10.1.Overview
10.2.Global Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
10.2.1.Early Cancer Screening
10.2.1.1.Definition
10.2.1.2.Market Estimation and Penetration, 2016 – 2023
10.2.1.3.Market Forecast, 2024 – 2034
10.2.1.4.Compound Annual Growth Rate (CAGR)
10.2.1.5.Regional Bifurcation
10.2.1.5.1.North America
10.2.1.5.1.1.Market Estimation, 2016 – 2023
10.2.1.5.1.2.Market Forecast, 2024 – 2034
10.2.1.5.2.Europe
10.2.1.5.2.1.Market Estimation, 2016 – 2023
10.2.1.5.2.2.Market Forecast, 2024 – 2034
10.2.1.5.3.Asia Pacific
10.2.1.5.3.1.Market Estimation, 2016 – 2023
10.2.1.5.3.2.Market Forecast, 2024 – 2034
10.2.1.5.4.Middle East and Africa
10.2.1.5.4.1.Market Estimation, 2016 – 2023
10.2.1.5.4.2.Market Forecast, 2024 – 2034
10.2.1.5.5.Latin America
10.2.1.5.5.1.Market Estimation, 2016 – 2023
10.2.1.5.5.2.Market Forecast, 2024 – 2034
10.2.2.Therapy Selection
10.2.2.1.Definition
10.2.2.2.Market Estimation and Penetration, 2016 – 2023
10.2.2.3.Market Forecast, 2024 – 2034
10.2.2.4.Compound Annual Growth Rate (CAGR)
10.2.2.5.Regional Bifurcation
10.2.2.5.1.North America
10.2.2.5.1.1.Market Estimation, 2016 – 2023
10.2.2.5.1.2.Market Forecast, 2024 – 2034
10.2.2.5.2.Europe
10.2.2.5.2.1.Market Estimation, 2016 – 2023
10.2.2.5.2.2.Market Forecast, 2024 – 2034
10.2.2.5.3.Asia Pacific
10.2.2.5.3.1.Market Estimation, 2016 – 2023
10.2.2.5.3.2.Market Forecast, 2024 – 2034
10.2.2.5.4.Middle East and Africa
10.2.2.5.4.1.Market Estimation, 2016 – 2023
10.2.2.5.4.2.Market Forecast, 2024 – 2034
10.2.2.5.5.Latin America
10.2.2.5.5.1.Market Estimation, 2016 – 2023
10.2.2.5.5.2.Market Forecast, 2024 – 2034
10.2.3.Treatment Monitoring
10.2.3.1.Definition
10.2.3.2.Market Estimation and Penetration, 2016 – 2023
10.2.3.3.Market Forecast, 2024 – 2034
10.2.3.4.Compound Annual Growth Rate (CAGR)
10.2.3.5.Regional Bifurcation
10.2.3.5.1.North America
10.2.3.5.1.1.Market Estimation, 2016 – 2023
10.2.3.5.1.2.Market Forecast, 2024 – 2034
10.2.3.5.2.Europe
10.2.3.5.2.1.Market Estimation, 2016 – 2023
10.2.3.5.2.2.Market Forecast, 2024 – 2034
10.2.3.5.3.Asia Pacific
10.2.3.5.3.1.Market Estimation, 2016 – 2023
10.2.3.5.3.2.Market Forecast, 2024 – 2034
10.2.3.5.4.Middle East and Africa
10.2.3.5.4.1.Market Estimation, 2016 – 2023
10.2.3.5.4.2.Market Forecast, 2024 – 2034
10.2.3.5.5.Latin America
10.2.3.5.5.1.Market Estimation, 2016 – 2023
10.2.3.5.5.2.Market Forecast, 2024 – 2034
10.2.4.Recurrence Monitoring
10.2.4.1.Definition
10.2.4.2.Market Estimation and Penetration, 2016 – 2023
10.2.4.3.Market Forecast, 2024 – 2034
10.2.4.4.Compound Annual Growth Rate (CAGR)
10.2.4.5.Regional Bifurcation
10.2.4.5.1.North America
10.2.4.5.1.1.Market Estimation, 2016 – 2023
10.2.4.5.1.2.Market Forecast, 2024 – 2034
10.2.4.5.2.Europe
10.2.4.5.2.1.Market Estimation, 2016 – 2023
10.2.4.5.2.2.Market Forecast, 2024 – 2034
10.2.4.5.3.Asia Pacific
10.2.4.5.3.1.Market Estimation, 2016 – 2023
10.2.4.5.3.2.Market Forecast, 2024 – 2034
10.2.4.5.4.Middle East and Africa
10.2.4.5.4.1.Market Estimation, 2016 – 2023
10.2.4.5.4.2.Market Forecast, 2024 – 2034
10.2.4.5.5.Latin America
10.2.4.5.5.1.Market Estimation, 2016 – 2023
10.2.4.5.5.2.Market Forecast, 2024 – 2034
10.3.Key Segment for Channeling Investments
10.3.1.By Clinical Application
11.Global Liquid Biopsy Market Analysis and Forecasts, 2024 – 2034
11.1.Overview
11.2.Global Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
11.2.1.Multi-gene Parallel Analysis using NGS
11.2.1.1.Definition
11.2.1.2.Market Estimation and Penetration, 2016 – 2023
11.2.1.3.Market Forecast, 2024 – 2034
11.2.1.4.Compound Annual Growth Rate (CAGR)
11.2.1.5.Regional Bifurcation
11.2.1.5.1.North America
11.2.1.5.1.1.Market Estimation, 2016 – 2023
11.2.1.5.1.2.Market Forecast, 2024 – 2034
11.2.1.5.2.Europe
11.2.1.5.2.1.Market Estimation, 2016 – 2023
11.2.1.5.2.2.Market Forecast, 2024 – 2034
11.2.1.5.3.Asia Pacific
11.2.1.5.3.1.Market Estimation, 2016 – 2023
11.2.1.5.3.2.Market Forecast, 2024 – 2034
11.2.1.5.4.Middle East and Africa
11.2.1.5.4.1.Market Estimation, 2016 – 2023
11.2.1.5.4.2.Market Forecast, 2024 – 2034
11.2.1.5.5.Latin America
11.2.1.5.5.1.Market Estimation, 2016 – 2023
11.2.1.5.5.2.Market Forecast, 2024 – 2034
11.2.2.Single-gene Analysis using PCR
11.2.2.1.Definition
11.2.2.2.Market Estimation and Penetration, 2016 – 2023
11.2.2.3.Market Forecast, 2024 – 2034
11.2.2.4.Compound Annual Growth Rate (CAGR)
11.2.2.5.Regional Bifurcation
11.2.2.5.1.North America
11.2.2.5.1.1.Market Estimation, 2016 – 2023
11.2.2.5.1.2.Market Forecast, 2024 – 2034
11.2.2.5.2.Europe
11.2.2.5.2.1.Market Estimation, 2016 – 2023
11.2.2.5.2.2.Market Forecast, 2024 – 2034
11.2.2.5.3.Asia Pacific
11.2.2.5.3.1.Market Estimation, 2016 – 2023
11.2.2.5.3.2.Market Forecast, 2024 – 2034
11.2.2.5.4.Middle East and Africa
11.2.2.5.4.1.Market Estimation, 2016 – 2023
11.2.2.5.4.2.Market Forecast, 2024 – 2034
11.2.2.5.5.Latin America
11.2.2.5.5.1.Market Estimation, 2016 – 2023
11.2.2.5.5.2.Market Forecast, 2024 – 2034
11.3.Key Segment for Channeling Investments
11.3.1.By Technology
12.Global Liquid Biopsy Market Analysis and Forecasts, 2024 – 2034
12.1.Overview
12.2.Global Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
12.2.1.Cancer Applications (Definition, Market Estimation and Penetration, 2016 – 2023, Market Estimation (2016 – 2023), Market Forecast (2024 – 2034), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Cancers)
12.2.1.1.Lung Cancer
12.2.1.2.Breast Cancer
12.2.1.3.Colorectal Cancer
12.2.1.4.Prostate Cancer
12.2.1.5.Melanoma
12.2.1.6.Other Cancers
12.2.2.Non-cancer Applications (Definition, Market Estimation and Penetration, 2016 – 2023, Market Estimation (2016 – 2023), Market Forecast (2024 – 2034), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Non-Invasive Prenatal Testing, Organ Transplantation, Infectious Disease Testing)
12.2.2.1.Non-Invasive Prenatal Testing
12.2.2.2.Organ Transplantation
12.2.2.3.Infectious Disease Testing
12.3.Key Segment for Channeling Investments
12.3.1.By Application
13.Global Liquid Biopsy Market Analysis and Forecasts, 2024 – 2034
13.1.Overview
13.2.Global Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
13.2.1.Blood Sample
13.2.1.1.Definition
13.2.1.2.Market Estimation and Penetration, 2016 – 2023
13.2.1.3.Market Forecast, 2024 – 2034
13.2.1.4.Compound Annual Growth Rate (CAGR)
13.2.1.5.Regional Bifurcation
13.2.1.5.1.North America
13.2.1.5.1.1.Market Estimation, 2016 – 2023
13.2.1.5.1.2.Market Forecast, 2024 – 2034
13.2.1.5.2.Europe
13.2.1.5.2.1.Market Estimation, 2016 – 2023
13.2.1.5.2.2.Market Forecast, 2024 – 2034
13.2.1.5.3.Asia Pacific
13.2.1.5.3.1.Market Estimation, 2016 – 2023
13.2.1.5.3.2.Market Forecast, 2024 – 2034
13.2.1.5.4.Middle East and Africa
13.2.1.5.4.1.Market Estimation, 2016 – 2023
13.2.1.5.4.2.Market Forecast, 2024 – 2034
13.2.1.5.5.Latin America
13.2.1.5.5.1.Market Estimation, 2016 – 2023
13.2.1.5.5.2.Market Forecast, 2024 – 2034
13.2.2.Other Sample Types
13.2.2.1.Definition
13.2.2.2.Market Estimation and Penetration, 2016 – 2023
13.2.2.3.Market Forecast, 2024 – 2034
13.2.2.4.Compound Annual Growth Rate (CAGR)
13.2.2.5.Regional Bifurcation
13.2.2.5.1.North America
13.2.2.5.1.1.Market Estimation, 2016 – 2023
13.2.2.5.1.2.Market Forecast, 2024 – 2034
13.2.2.5.2.Europe
13.2.2.5.2.1.Market Estimation, 2016 – 2023
13.2.2.5.2.2.Market Forecast, 2024 – 2034
13.2.2.5.3.Asia Pacific
13.2.2.5.3.1.Market Estimation, 2016 – 2023
13.2.2.5.3.2.Market Forecast, 2024 – 2034
13.2.2.5.4.Middle East and Africa
13.2.2.5.4.1.Market Estimation, 2016 – 2023
13.2.2.5.4.2.Market Forecast, 2024 – 2034
13.2.2.5.5.Latin America
13.2.2.5.5.1.Market Estimation, 2016 – 2023
13.2.2.5.5.2.Market Forecast, 2024 – 2034
13.3.Key Segment for Channeling Investments
13.3.1.By Sample Type
14.Global Liquid Biopsy Market Analysis and Forecasts, 2024 – 2034
14.1.Overview
14.2.Global Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
14.2.1.Reference Laboratories
14.2.1.1.Definition
14.2.1.2.Market Estimation and Penetration, 2016 – 2023
14.2.1.3.Market Forecast, 2024 – 2034
14.2.1.4.Compound Annual Growth Rate (CAGR)
14.2.1.5.Regional Bifurcation
14.2.1.5.1.North America
14.2.1.5.1.1.Market Estimation, 2016 – 2023
14.2.1.5.1.2.Market Forecast, 2024 – 2034
14.2.1.5.2.Europe
14.2.1.5.2.1.Market Estimation, 2016 – 2023
14.2.1.5.2.2.Market Forecast, 2024 – 2034
14.2.1.5.3.Asia Pacific
14.2.1.5.3.1.Market Estimation, 2016 – 2023
14.2.1.5.3.2.Market Forecast, 2024 – 2034
14.2.1.5.4.Middle East and Africa
14.2.1.5.4.1.Market Estimation, 2016 – 2023
14.2.1.5.4.2.Market Forecast, 2024 – 2034
14.2.1.5.5.Latin America
14.2.1.5.5.1.Market Estimation, 2016 – 2023
14.2.1.5.5.2.Market Forecast, 2024 – 2034
14.2.2.Hospitals and Physician Laboratories
14.2.2.1.Definition
14.2.2.2.Market Estimation and Penetration, 2016 – 2023
14.2.2.3.Market Forecast, 2024 – 2034
14.2.2.4.Compound Annual Growth Rate (CAGR)
14.2.2.5.Regional Bifurcation
14.2.2.5.1.North America
14.2.2.5.1.1.Market Estimation, 2016 – 2023
14.2.2.5.1.2.Market Forecast, 2024 – 2034
14.2.2.5.2.Europe
14.2.2.5.2.1.Market Estimation, 2016 – 2023
14.2.2.5.2.2.Market Forecast, 2024 – 2034
14.2.2.5.3.Asia Pacific
14.2.2.5.3.1.Market Estimation, 2016 – 2023
14.2.2.5.3.2.Market Forecast, 2024 – 2034
14.2.2.5.4.Middle East and Africa
14.2.2.5.4.1.Market Estimation, 2016 – 2023
14.2.2.5.4.2.Market Forecast, 2024 – 2034
14.2.2.5.5.Latin America
14.2.2.5.5.1.Market Estimation, 2016 – 2023
14.2.2.5.5.2.Market Forecast, 2024 – 2034
14.2.3.Academic and Research Centers
14.2.3.1.Definition
14.2.3.2.Market Estimation and Penetration, 2016 – 2023
14.2.3.3.Market Forecast, 2024 – 2034
14.2.3.4.Compound Annual Growth Rate (CAGR)
14.2.3.5.Regional Bifurcation
14.2.3.5.1.North America
14.2.3.5.1.1.Market Estimation, 2016 – 2023
14.2.3.5.1.2.Market Forecast, 2024 – 2034
14.2.3.5.2.Europe
14.2.3.5.2.1.Market Estimation, 2016 – 2023
14.2.3.5.2.2.Market Forecast, 2024 – 2034
14.2.3.5.3.Asia Pacific
14.2.3.5.3.1.Market Estimation, 2016 – 2023
14.2.3.5.3.2.Market Forecast, 2024 – 2034
14.2.3.5.4.Middle East and Africa
14.2.3.5.4.1.Market Estimation, 2016 – 2023
14.2.3.5.4.2.Market Forecast, 2024 – 2034
14.2.3.5.5.Latin America
14.2.3.5.5.1.Market Estimation, 2016 – 2023
14.2.3.5.5.2.Market Forecast, 2024 – 2034
14.2.4.Other End Users
14.2.4.1.Definition
14.2.4.2.Market Estimation and Penetration, 2016 – 2023
14.2.4.3.Market Forecast, 2024 – 2034
14.2.4.4.Compound Annual Growth Rate (CAGR)
14.2.4.5.Regional Bifurcation
14.2.4.5.1.North America
14.2.4.5.1.1.Market Estimation, 2016 – 2023
14.2.4.5.1.2.Market Forecast, 2024 – 2034
14.2.4.5.2.Europe
14.2.4.5.2.1.Market Estimation, 2016 – 2023
14.2.4.5.2.2.Market Forecast, 2024 – 2034
14.2.4.5.3.Asia Pacific
14.2.4.5.3.1.Market Estimation, 2016 – 2023
14.2.4.5.3.2.Market Forecast, 2024 – 2034
14.2.4.5.4.Middle East and Africa
14.2.4.5.4.1.Market Estimation, 2016 – 2023
14.2.4.5.4.2.Market Forecast, 2024 – 2034
14.2.4.5.5.Latin America
14.2.4.5.5.1.Market Estimation, 2016 – 2023
14.2.4.5.5.2.Market Forecast, 2024 – 2034
14.3.Key Segment for Channeling Investments
14.3.1.By End User
15.North America Liquid Biopsy Market Analysis and Forecasts, 2024 – 2034
15.1.Overview
15.1.1.North America Liquid Biopsy Market Revenue (US$ Mn)
15.2.North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
15.2.1.Assay Kits
15.2.2.Instruments
15.2.3.Services
15.3.North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
15.3.1.Circulating Tumor Cells
15.3.2.Circulating Tumor DNA
15.3.3.Cell-free DNA
15.3.4.Extracellular Vesicles
15.3.5.Other Circulating Biomarkers
15.4.North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
15.4.1.Early Cancer Screening
15.4.2.Therapy Selection
15.4.3.Treatment Monitoring
15.4.4.Recurrence Monitoring
15.5.North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
15.5.1.Multi-gene Parallel Analysis using NGS
15.5.2.Single-gene Analysis using PCR
15.6.North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
15.6.1.Cancer Applications
15.6.1.1.Lung Cancer
15.6.1.2.Breast Cancer
15.6.1.3.Colorectal Cancer
15.6.1.4.Prostate Cancer
15.6.1.5.Melanoma
15.6.1.6.Other Cancers
15.6.2.Non-cancer Applications
15.6.2.1.Non-Invasive Prenatal Testing
15.6.2.2.Organ Transplantation
15.6.2.3.Infectious Disease Testing
15.7.North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.7.1.Blood Sample
15.7.2.Other Sample Types
15.8.North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
15.8.1.Reference Laboratories
15.8.2.Hospitals and Physician Laboratories
15.8.3.Academic and Research Centers
15.8.4.Other End Users
15.9.North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Country
15.9.1.U.S
15.9.1.1.U.S Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
15.9.1.1.1.Assay Kits
15.9.1.1.2.Instruments
15.9.1.1.3.Services
15.9.1.2.U.S Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
15.9.1.2.1.Circulating Tumor Cells
15.9.1.2.2.Circulating Tumor DNA
15.9.1.2.3.Cell-free DNA
15.9.1.2.4.Extracellular Vesicles
15.9.1.2.5.Other Circulating Biomarkers
15.9.1.3.U.S Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
15.9.1.3.1.Early Cancer Screening
15.9.1.3.2.Therapy Selection
15.9.1.3.3.Treatment Monitoring
15.9.1.3.4.Recurrence Monitoring
15.9.1.4.U.S Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
15.9.1.4.1.Multi-gene Parallel Analysis using NGS
15.9.1.4.2.Single-gene Analysis using PCR
15.9.1.5.U.S Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
15.9.1.5.1.Cancer Applications
15.9.1.5.1.1.Lung Cancer
15.9.1.5.1.2.Breast Cancer
15.9.1.5.1.3.Colorectal Cancer
15.9.1.5.1.4.Prostate Cancer
15.9.1.5.1.5.Melanoma
15.9.1.5.1.6.Other Cancers
15.9.1.5.2.Non-cancer Applications
15.9.1.5.2.1.Non-Invasive Prenatal Testing
15.9.1.5.2.2.Organ Transplantation
15.9.1.5.2.3.Infectious Disease Testing
15.9.1.6.U.S Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.9.1.6.1.Blood Sample
15.9.1.6.2.Other Sample Types
15.9.1.7.U.S Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
15.9.1.7.1.Reference Laboratories
15.9.1.7.2.Hospitals and Physician Laboratories
15.9.1.7.3.Academic and Research Centers
15.9.1.7.4.Other End Users
15.9.2.Canada
15.9.2.1.Canada Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
15.9.2.1.1.Assay Kits
15.9.2.1.2.Instruments
15.9.2.1.3.Services
15.9.2.2.Canada Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
15.9.2.2.1.Circulating Tumor Cells
15.9.2.2.2.Circulating Tumor DNA
15.9.2.2.3.Cell-free DNA
15.9.2.2.4.Extracellular Vesicles
15.9.2.2.5.Other Circulating Biomarkers
15.9.2.3.Canada Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
15.9.2.3.1.Early Cancer Screening
15.9.2.3.2.Therapy Selection
15.9.2.3.3.Treatment Monitoring
15.9.2.3.4.Recurrence Monitoring
15.9.2.4.Canada Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
15.9.2.4.1.Multi-gene Parallel Analysis using NGS
15.9.2.4.2.Single-gene Analysis using PCR
15.9.2.5.Canada Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
15.9.2.5.1.Cancer Applications
15.9.2.5.1.1.Lung Cancer
15.9.2.5.1.2.Breast Cancer
15.9.2.5.1.3.Colorectal Cancer
15.9.2.5.1.4.Prostate Cancer
15.9.2.5.1.5.Melanoma
15.9.2.5.1.6.Other Cancers
15.9.2.5.2.Non-cancer Applications
15.9.2.5.2.1.Non-Invasive Prenatal Testing
15.9.2.5.2.2.Organ Transplantation
15.9.2.5.2.3.Infectious Disease Testing
15.9.2.6.Canada Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.9.2.6.1.Blood Sample
15.9.2.6.2.Other Sample Types
15.9.2.7.Canada Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
15.9.2.7.1.Reference Laboratories
15.9.2.7.2.Hospitals and Physician Laboratories
15.9.2.7.3.Academic and Research Centers
15.9.2.7.4.Other End Users
15.9.3.Mexico
15.9.3.1.Mexico Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
15.9.3.1.1.Assay Kits
15.9.3.1.2.Instruments
15.9.3.1.3.Services
15.9.3.2.Mexico Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
15.9.3.2.1.Circulating Tumor Cells
15.9.3.2.2.Circulating Tumor DNA
15.9.3.2.3.Cell-free DNA
15.9.3.2.4.Extracellular Vesicles
15.9.3.2.5.Other Circulating Biomarkers
15.9.3.3.Mexico Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
15.9.3.3.1.Early Cancer Screening
15.9.3.3.2.Therapy Selection
15.9.3.3.3.Treatment Monitoring
15.9.3.3.4.Recurrence Monitoring
15.9.3.4.Mexico Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
15.9.3.4.1.Multi-gene Parallel Analysis using NGS
15.9.3.4.2.Single-gene Analysis using PCR
15.9.3.5.Mexico Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
15.9.3.5.1.Cancer Applications
15.9.3.5.1.1.Lung Cancer
15.9.3.5.1.2.Breast Cancer
15.9.3.5.1.3.Colorectal Cancer
15.9.3.5.1.4.Prostate Cancer
15.9.3.5.1.5.Melanoma
15.9.3.5.1.6.Other Cancers
15.9.3.5.2.Non-cancer Applications
15.9.3.5.2.1.Non-Invasive Prenatal Testing
15.9.3.5.2.2.Organ Transplantation
15.9.3.5.2.3.Infectious Disease Testing
15.9.3.6.Mexico Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.9.3.6.1.Blood Sample
15.9.3.6.2.Other Sample Types
15.9.3.7.Mexico Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
15.9.3.7.1.Reference Laboratories
15.9.3.7.2.Hospitals and Physician Laboratories
15.9.3.7.3.Academic and Research Centers
15.9.3.7.4.Other End Users
15.9.4.Rest of North America
15.9.4.1.Rest of North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
15.9.4.1.1.Assay Kits
15.9.4.1.2.Instruments
15.9.4.1.3.Services
15.9.4.2.Rest of North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
15.9.4.2.1.Circulating Tumor Cells
15.9.4.2.2.Circulating Tumor DNA
15.9.4.2.3.Cell-free DNA
15.9.4.2.4.Extracellular Vesicles
15.9.4.2.5.Other Circulating Biomarkers
15.9.4.3.Rest of North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
15.9.4.3.1.Early Cancer Screening
15.9.4.3.2.Therapy Selection
15.9.4.3.3.Treatment Monitoring
15.9.4.3.4.Recurrence Monitoring
15.9.4.4.Rest of North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
15.9.4.4.1.Multi-gene Parallel Analysis using NGS
15.9.4.4.2.Single-gene Analysis using PCR
15.9.4.5.Rest of North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
15.9.4.5.1.Cancer Applications
15.9.4.5.1.1.Lung Cancer
15.9.4.5.1.2.Breast Cancer
15.9.4.5.1.3.Colorectal Cancer
15.9.4.5.1.4.Prostate Cancer
15.9.4.5.1.5.Melanoma
15.9.4.5.1.6.Other Cancers
15.9.4.5.2.Non-cancer Applications
15.9.4.5.2.1.Non-Invasive Prenatal Testing
15.9.4.5.2.2.Organ Transplantation
15.9.4.5.2.3.Infectious Disease Testing
15.9.4.6.Rest of North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.9.4.6.1.Blood Sample
15.9.4.6.2.Other Sample Types
15.9.4.7.Rest of North America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
15.9.4.7.1.Reference Laboratories
15.9.4.7.2.Hospitals and Physician Laboratories
15.9.4.7.3.Academic and Research Centers
15.9.4.7.4.Other End Users
15.10.Key Segment for Channeling Investments
15.10.1.By Country
15.10.2.By Product and Service
15.10.3.By Circulating Biomarker
15.10.4.By Clinical Application
15.10.5.By Technology
15.10.6.By Application
15.10.7.By Sample Type
15.10.8.By End User
16.Europe Liquid Biopsy Market Analysis and Forecasts, 2024 – 2034
16.1.Overview
16.1.1.Europe Liquid Biopsy Market Revenue (US$ Mn)
16.2.Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
16.2.1.Assay Kits
16.2.2.Instruments
16.2.3.Services
16.3.Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
16.3.1.Circulating Tumor Cells
16.3.2.Circulating Tumor DNA
16.3.3.Cell-free DNA
16.3.4.Extracellular Vesicles
16.3.5.Other Circulating Biomarkers
16.4.Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
16.4.1.Early Cancer Screening
16.4.2.Therapy Selection
16.4.3.Treatment Monitoring
16.4.4.Recurrence Monitoring
16.5.Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
16.5.1.Multi-gene Parallel Analysis using NGS
16.5.2.Single-gene Analysis using PCR
16.6.Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
16.6.1.Cancer Applications
16.6.1.1.Lung Cancer
16.6.1.2.Breast Cancer
16.6.1.3.Colorectal Cancer
16.6.1.4.Prostate Cancer
16.6.1.5.Melanoma
16.6.1.6.Other Cancers
16.6.2.Non-cancer Applications
16.6.2.1.Non-Invasive Prenatal Testing
16.6.2.2.Organ Transplantation
16.6.2.3.Infectious Disease Testing
16.7.Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.7.1.Blood Sample
16.7.2.Other Sample Types
16.8.Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
16.8.1.Reference Laboratories
16.8.2.Hospitals and Physician Laboratories
16.8.3.Academic and Research Centers
16.8.4.Other End Users
16.9.Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Country
16.9.1.France
16.9.1.1.France Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
16.9.1.1.1.Assay Kits
16.9.1.1.2.Instruments
16.9.1.1.3.Services
16.9.1.2.France Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
16.9.1.2.1.Circulating Tumor Cells
16.9.1.2.2.Circulating Tumor DNA
16.9.1.2.3.Cell-free DNA
16.9.1.2.4.Extracellular Vesicles
16.9.1.2.5.Other Circulating Biomarkers
16.9.1.3.France Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
16.9.1.3.1.Early Cancer Screening
16.9.1.3.2.Therapy Selection
16.9.1.3.3.Treatment Monitoring
16.9.1.3.4.Recurrence Monitoring
16.9.1.4.France Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.1.4.1.Multi-gene Parallel Analysis using NGS
16.9.1.4.2.Single-gene Analysis using PCR
16.9.1.5.France Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
16.9.1.5.1.Cancer Applications
16.9.1.5.1.1.Lung Cancer
16.9.1.5.1.2.Breast Cancer
16.9.1.5.1.3.Colorectal Cancer
16.9.1.5.1.4.Prostate Cancer
16.9.1.5.1.5.Melanoma
16.9.1.5.1.6.Other Cancers
16.9.1.5.2.Non-cancer Applications
16.9.1.5.2.1.Non-Invasive Prenatal Testing
16.9.1.5.2.2.Organ Transplantation
16.9.1.5.2.3.Infectious Disease Testing
16.9.1.6.France Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.9.1.6.1.Blood Sample
16.9.1.6.2.Other Sample Types
16.9.1.7.France Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
16.9.1.7.1.Reference Laboratories
16.9.1.7.2.Hospitals and Physician Laboratories
16.9.1.7.3.Academic and Research Centers
16.9.1.7.4.Other End Users
16.9.2.The UK
16.9.2.1.The UK Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
16.9.2.1.1.Assay Kits
16.9.2.1.2.Instruments
16.9.2.1.3.Services
16.9.2.2.The UK Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
16.9.2.2.1.Circulating Tumor Cells
16.9.2.2.2.Circulating Tumor DNA
16.9.2.2.3.Cell-free DNA
16.9.2.2.4.Extracellular Vesicles
16.9.2.2.5.Other Circulating Biomarkers
16.9.2.3.The UK Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
16.9.2.3.1.Early Cancer Screening
16.9.2.3.2.Therapy Selection
16.9.2.3.3.Treatment Monitoring
16.9.2.3.4.Recurrence Monitoring
16.9.2.4.The UK Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.2.4.1.Multi-gene Parallel Analysis using NGS
16.9.2.4.2.Single-gene Analysis using PCR
16.9.2.5.The UK Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
16.9.2.5.1.Cancer Applications
16.9.2.5.1.1.Lung Cancer
16.9.2.5.1.2.Breast Cancer
16.9.2.5.1.3.Colorectal Cancer
16.9.2.5.1.4.Prostate Cancer
16.9.2.5.1.5.Melanoma
16.9.2.5.1.6.Other Cancers
16.9.2.5.2.Non-cancer Applications
16.9.2.5.2.1.Non-Invasive Prenatal Testing
16.9.2.5.2.2.Organ Transplantation
16.9.2.5.2.3.Infectious Disease Testing
16.9.2.6.The UK Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.9.2.6.1.Blood Sample
16.9.2.6.2.Other Sample Types
16.9.2.7.The UK Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
16.9.2.7.1.Reference Laboratories
16.9.2.7.2.Hospitals and Physician Laboratories
16.9.2.7.3.Academic and Research Centers
16.9.2.7.4.Other End Users
16.9.3.Spain
16.9.3.1.Spain Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
16.9.3.1.1.Assay Kits
16.9.3.1.2.Instruments
16.9.3.1.3.Services
16.9.3.2.Spain Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
16.9.3.2.1.Circulating Tumor Cells
16.9.3.2.2.Circulating Tumor DNA
16.9.3.2.3.Cell-free DNA
16.9.3.2.4.Extracellular Vesicles
16.9.3.2.5.Other Circulating Biomarkers
16.9.3.3.Spain Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
16.9.3.3.1.Early Cancer Screening
16.9.3.3.2.Therapy Selection
16.9.3.3.3.Treatment Monitoring
16.9.3.3.4.Recurrence Monitoring
16.9.3.4.Spain Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.3.4.1.Multi-gene Parallel Analysis using NGS
16.9.3.4.2.Single-gene Analysis using PCR
16.9.3.5.Spain Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
16.9.3.5.1.Cancer Applications
16.9.3.5.1.1.Lung Cancer
16.9.3.5.1.2.Breast Cancer
16.9.3.5.1.3.Colorectal Cancer
16.9.3.5.1.4.Prostate Cancer
16.9.3.5.1.5.Melanoma
16.9.3.5.1.6.Other Cancers
16.9.3.5.2.Non-cancer Applications
16.9.3.5.2.1.Non-Invasive Prenatal Testing
16.9.3.5.2.2.Organ Transplantation
16.9.3.5.2.3.Infectious Disease Testing
16.9.3.6.Spain Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.9.3.6.1.Blood Sample
16.9.3.6.2.Other Sample Types
16.9.3.7.Spain Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
16.9.3.7.1.Reference Laboratories
16.9.3.7.2.Hospitals and Physician Laboratories
16.9.3.7.3.Academic and Research Centers
16.9.3.7.4.Other End Users
16.9.4.Germany
16.9.4.1.Germany Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
16.9.4.1.1.Assay Kits
16.9.4.1.2.Instruments
16.9.4.1.3.Services
16.9.4.2.Germany Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
16.9.4.2.1.Circulating Tumor Cells
16.9.4.2.2.Circulating Tumor DNA
16.9.4.2.3.Cell-free DNA
16.9.4.2.4.Extracellular Vesicles
16.9.4.2.5.Other Circulating Biomarkers
16.9.4.3.Germany Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
16.9.4.3.1.Early Cancer Screening
16.9.4.3.2.Therapy Selection
16.9.4.3.3.Treatment Monitoring
16.9.4.3.4.Recurrence Monitoring
16.9.4.4.Germany Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.4.4.1.Multi-gene Parallel Analysis using NGS
16.9.4.4.2.Single-gene Analysis using PCR
16.9.4.5.Germany Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
16.9.4.5.1.Cancer Applications
16.9.4.5.1.1.Lung Cancer
16.9.4.5.1.2.Breast Cancer
16.9.4.5.1.3.Colorectal Cancer
16.9.4.5.1.4.Prostate Cancer
16.9.4.5.1.5.Melanoma
16.9.4.5.1.6.Other Cancers
16.9.4.5.2.Non-cancer Applications
16.9.4.5.2.1.Non-Invasive Prenatal Testing
16.9.4.5.2.2.Organ Transplantation
16.9.4.5.2.3.Infectious Disease Testing
16.9.4.6.Germany Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.9.4.6.1.Blood Sample
16.9.4.6.2.Other Sample Types
16.9.4.7.Germany Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
16.9.4.7.1.Reference Laboratories
16.9.4.7.2.Hospitals and Physician Laboratories
16.9.4.7.3.Academic and Research Centers
16.9.4.7.4.Other End Users
16.9.5.Italy
16.9.5.1.Italy Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
16.9.5.1.1.Assay Kits
16.9.5.1.2.Instruments
16.9.5.1.3.Services
16.9.5.2.Italy Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
16.9.5.2.1.Circulating Tumor Cells
16.9.5.2.2.Circulating Tumor DNA
16.9.5.2.3.Cell-free DNA
16.9.5.2.4.Extracellular Vesicles
16.9.5.2.5.Other Circulating Biomarkers
16.9.5.3.Italy Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
16.9.5.3.1.Early Cancer Screening
16.9.5.3.2.Therapy Selection
16.9.5.3.3.Treatment Monitoring
16.9.5.3.4.Recurrence Monitoring
16.9.5.4.Italy Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.5.4.1.Multi-gene Parallel Analysis using NGS
16.9.5.4.2.Single-gene Analysis using PCR
16.9.5.5.Italy Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
16.9.5.5.1.Cancer Applications
16.9.5.5.1.1.Lung Cancer
16.9.5.5.1.2.Breast Cancer
16.9.5.5.1.3.Colorectal Cancer
16.9.5.5.1.4.Prostate Cancer
16.9.5.5.1.5.Melanoma
16.9.5.5.1.6.Other Cancers
16.9.5.5.2.Non-cancer Applications
16.9.5.5.2.1.Non-Invasive Prenatal Testing
16.9.5.5.2.2.Organ Transplantation
16.9.5.5.2.3.Infectious Disease Testing
16.9.5.6.Italy Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.9.5.6.1.Blood Sample
16.9.5.6.2.Other Sample Types
16.9.5.7.Italy Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
16.9.5.7.1.Reference Laboratories
16.9.5.7.2.Hospitals and Physician Laboratories
16.9.5.7.3.Academic and Research Centers
16.9.5.7.4.Other End Users
16.9.6.Nordic Countries
16.9.6.1.Nordic Countries Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
16.9.6.1.1.Assay Kits
16.9.6.1.2.Instruments
16.9.6.1.3.Services
16.9.6.2.Nordic Countries Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
16.9.6.2.1.Circulating Tumor Cells
16.9.6.2.2.Circulating Tumor DNA
16.9.6.2.3.Cell-free DNA
16.9.6.2.4.Extracellular Vesicles
16.9.6.2.5.Other Circulating Biomarkers
16.9.6.3.Nordic Countries Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
16.9.6.3.1.Early Cancer Screening
16.9.6.3.2.Therapy Selection
16.9.6.3.3.Treatment Monitoring
16.9.6.3.4.Recurrence Monitoring
16.9.6.4.Nordic Countries Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.6.4.1.Multi-gene Parallel Analysis using NGS
16.9.6.4.2.Single-gene Analysis using PCR
16.9.6.5.Nordic Countries Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
16.9.6.5.1.Cancer Applications
16.9.6.5.1.1.Lung Cancer
16.9.6.5.1.2.Breast Cancer
16.9.6.5.1.3.Colorectal Cancer
16.9.6.5.1.4.Prostate Cancer
16.9.6.5.1.5.Melanoma
16.9.6.5.1.6.Other Cancers
16.9.6.5.2.Non-cancer Applications
16.9.6.5.2.1.Non-Invasive Prenatal Testing
16.9.6.5.2.2.Organ Transplantation
16.9.6.5.2.3.Infectious Disease Testing
16.9.6.6.Nordic Countries Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.9.6.6.1.Blood Sample
16.9.6.6.2.Other Sample Types
16.9.6.7.Nordic Countries Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
16.9.6.7.1.Reference Laboratories
16.9.6.7.2.Hospitals and Physician Laboratories
16.9.6.7.3.Academic and Research Centers
16.9.6.7.4.Other End Users
16.9.6.8.Nordic Countries Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Country
16.9.6.8.1.Denmark
16.9.6.8.2.Finland
16.9.6.8.3.Iceland
16.9.6.8.4.Sweden
16.9.6.8.5.Norway
16.9.7.Benelux Union
16.9.7.1.Benelux Union Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
16.9.7.1.1.Assay Kits
16.9.7.1.2.Instruments
16.9.7.1.3.Services
16.9.7.2.Benelux Union Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
16.9.7.2.1.Circulating Tumor Cells
16.9.7.2.2.Circulating Tumor DNA
16.9.7.2.3.Cell-free DNA
16.9.7.2.4.Extracellular Vesicles
16.9.7.2.5.Other Circulating Biomarkers
16.9.7.3.Benelux Union Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
16.9.7.3.1.Early Cancer Screening
16.9.7.3.2.Therapy Selection
16.9.7.3.3.Treatment Monitoring
16.9.7.3.4.Recurrence Monitoring
16.9.7.4.Benelux Union Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.7.4.1.Multi-gene Parallel Analysis using NGS
16.9.7.4.2.Single-gene Analysis using PCR
16.9.7.5.Benelux Union Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
16.9.7.5.1.Cancer Applications
16.9.7.5.1.1.Lung Cancer
16.9.7.5.1.2.Breast Cancer
16.9.7.5.1.3.Colorectal Cancer
16.9.7.5.1.4.Prostate Cancer
16.9.7.5.1.5.Melanoma
16.9.7.5.1.6.Other Cancers
16.9.7.5.2.Non-cancer Applications
16.9.7.5.2.1.Non-Invasive Prenatal Testing
16.9.7.5.2.2.Organ Transplantation
16.9.7.5.2.3.Infectious Disease Testing
16.9.7.6.Benelux Union Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.9.7.6.1.Blood Sample
16.9.7.6.2.Other Sample Types
16.9.7.7.Benelux Union Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
16.9.7.7.1.Reference Laboratories
16.9.7.7.2.Hospitals and Physician Laboratories
16.9.7.7.3.Academic and Research Centers
16.9.7.7.4.Other End Users
16.9.7.8.Benelux Union Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Country
16.9.7.8.1.Belgium
16.9.7.8.2.The Netherlands
16.9.7.8.3.Luxembourg
16.9.8.Rest of Europe
16.9.8.1.Rest of Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
16.9.8.1.1.Assay Kits
16.9.8.1.2.Instruments
16.9.8.1.3.Services
16.9.8.2.Rest of Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
16.9.8.2.1.Circulating Tumor Cells
16.9.8.2.2.Circulating Tumor DNA
16.9.8.2.3.Cell-free DNA
16.9.8.2.4.Extracellular Vesicles
16.9.8.2.5.Other Circulating Biomarkers
16.9.8.3.Rest of Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
16.9.8.3.1.Early Cancer Screening
16.9.8.3.2.Therapy Selection
16.9.8.3.3.Treatment Monitoring
16.9.8.3.4.Recurrence Monitoring
16.9.8.4.Rest of Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
16.9.8.4.1.Multi-gene Parallel Analysis using NGS
16.9.8.4.2.Single-gene Analysis using PCR
16.9.8.5.Rest of Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
16.9.8.5.1.Cancer Applications
16.9.8.5.1.1.Lung Cancer
16.9.8.5.1.2.Breast Cancer
16.9.8.5.1.3.Colorectal Cancer
16.9.8.5.1.4.Prostate Cancer
16.9.8.5.1.5.Melanoma
16.9.8.5.1.6.Other Cancers
16.9.8.5.2.Non-cancer Applications
16.9.8.5.2.1.Non-Invasive Prenatal Testing
16.9.8.5.2.2.Organ Transplantation
16.9.8.5.2.3.Infectious Disease Testing
16.9.8.6.Rest of Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.9.8.6.1.Blood Sample
16.9.8.6.2.Other Sample Types
16.9.8.7.Rest of Europe Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
16.9.8.7.1.Reference Laboratories
16.9.8.7.2.Hospitals and Physician Laboratories
16.9.8.7.3.Academic and Research Centers
16.9.8.7.4.Other End Users
16.10.Key Segment for Channeling Investments
16.10.1.By Country
16.10.2.By Product and Service
16.10.3.By Circulating Biomarker
16.10.4.By Clinical Application
16.10.5.By Technology
16.10.6.By Application
16.10.7.By Sample Type
16.10.8.By End User
17.Asia Pacific Liquid Biopsy Market Analysis and Forecasts, 2024 – 2034
17.1.Overview
17.1.1.Asia Pacific Liquid Biopsy Market Revenue (US$ Mn)
17.2.Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
17.2.1.Assay Kits
17.2.2.Instruments
17.2.3.Services
17.3.Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
17.3.1.Circulating Tumor Cells
17.3.2.Circulating Tumor DNA
17.3.3.Cell-free DNA
17.3.4.Extracellular Vesicles
17.3.5.Other Circulating Biomarkers
17.4.Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
17.4.1.Early Cancer Screening
17.4.2.Therapy Selection
17.4.3.Treatment Monitoring
17.4.4.Recurrence Monitoring
17.5.Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
17.5.1.Multi-gene Parallel Analysis using NGS
17.5.2.Single-gene Analysis using PCR
17.6.Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
17.6.1.Cancer Applications
17.6.1.1.Lung Cancer
17.6.1.2.Breast Cancer
17.6.1.3.Colorectal Cancer
17.6.1.4.Prostate Cancer
17.6.1.5.Melanoma
17.6.1.6.Other Cancers
17.6.2.Non-cancer Applications
17.6.2.1.Non-Invasive Prenatal Testing
17.6.2.2.Organ Transplantation
17.6.2.3.Infectious Disease Testing
17.7.Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
17.7.1.Blood Sample
17.7.2.Other Sample Types
17.8.Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
17.8.1.Reference Laboratories
17.8.2.Hospitals and Physician Laboratories
17.8.3.Academic and Research Centers
17.8.4.Other End Users
17.9.Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Country
17.9.1.China
17.9.1.1.China Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
17.9.1.1.1.Assay Kits
17.9.1.1.2.Instruments
17.9.1.1.3.Services
17.9.1.2.China Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
17.9.1.2.1.Circulating Tumor Cells
17.9.1.2.2.Circulating Tumor DNA
17.9.1.2.3.Cell-free DNA
17.9.1.2.4.Extracellular Vesicles
17.9.1.2.5.Other Circulating Biomarkers
17.9.1.3.China Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
17.9.1.3.1.Early Cancer Screening
17.9.1.3.2.Therapy Selection
17.9.1.3.3.Treatment Monitoring
17.9.1.3.4.Recurrence Monitoring
17.9.1.4.China Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
17.9.1.4.1.Multi-gene Parallel Analysis using NGS
17.9.1.4.2.Single-gene Analysis using PCR
17.9.1.5.China Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
17.9.1.5.1.Cancer Applications
17.9.1.5.1.1.Lung Cancer
17.9.1.5.1.2.Breast Cancer
17.9.1.5.1.3.Colorectal Cancer
17.9.1.5.1.4.Prostate Cancer
17.9.1.5.1.5.Melanoma
17.9.1.5.1.6.Other Cancers
17.9.1.5.2.Non-cancer Applications
17.9.1.5.2.1.Non-Invasive Prenatal Testing
17.9.1.5.2.2.Organ Transplantation
17.9.1.5.2.3.Infectious Disease Testing
17.9.1.6.China Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
17.9.1.6.1.Blood Sample
17.9.1.6.2.Other Sample Types
17.9.1.7.China Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
17.9.1.7.1.Reference Laboratories
17.9.1.7.2.Hospitals and Physician Laboratories
17.9.1.7.3.Academic and Research Centers
17.9.1.7.4.Other End Users
17.9.2.Japan
17.9.2.1.Japan Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
17.9.2.1.1.Assay Kits
17.9.2.1.2.Instruments
17.9.2.1.3.Services
17.9.2.2.Japan Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
17.9.2.2.1.Circulating Tumor Cells
17.9.2.2.2.Circulating Tumor DNA
17.9.2.2.3.Cell-free DNA
17.9.2.2.4.Extracellular Vesicles
17.9.2.2.5.Other Circulating Biomarkers
17.9.2.3.Japan Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
17.9.2.3.1.Early Cancer Screening
17.9.2.3.2.Therapy Selection
17.9.2.3.3.Treatment Monitoring
17.9.2.3.4.Recurrence Monitoring
17.9.2.4.Japan Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
17.9.2.4.1.Multi-gene Parallel Analysis using NGS
17.9.2.4.2.Single-gene Analysis using PCR
17.9.2.5.Japan Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
17.9.2.5.1.Cancer Applications
17.9.2.5.1.1.Lung Cancer
17.9.2.5.1.2.Breast Cancer
17.9.2.5.1.3.Colorectal Cancer
17.9.2.5.1.4.Prostate Cancer
17.9.2.5.1.5.Melanoma
17.9.2.5.1.6.Other Cancers
17.9.2.5.2.Non-cancer Applications
17.9.2.5.2.1.Non-Invasive Prenatal Testing
17.9.2.5.2.2.Organ Transplantation
17.9.2.5.2.3.Infectious Disease Testing
17.9.2.6.Japan Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
17.9.2.6.1.Blood Sample
17.9.2.6.2.Other Sample Types
17.9.2.7.Japan Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
17.9.2.7.1.Reference Laboratories
17.9.2.7.2.Hospitals and Physician Laboratories
17.9.2.7.3.Academic and Research Centers
17.9.2.7.4.Other End Users
17.9.3.India
17.9.3.1.India Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
17.9.3.1.1.Assay Kits
17.9.3.1.2.Instruments
17.9.3.1.3.Services
17.9.3.2.India Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
17.9.3.2.1.Circulating Tumor Cells
17.9.3.2.2.Circulating Tumor DNA
17.9.3.2.3.Cell-free DNA
17.9.3.2.4.Extracellular Vesicles
17.9.3.2.5.Other Circulating Biomarkers
17.9.3.3.India Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
17.9.3.3.1.Early Cancer Screening
17.9.3.3.2.Therapy Selection
17.9.3.3.3.Treatment Monitoring
17.9.3.3.4.Recurrence Monitoring
17.9.3.4.India Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
17.9.3.4.1.Multi-gene Parallel Analysis using NGS
17.9.3.4.2.Single-gene Analysis using PCR
17.9.3.5.India Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
17.9.3.5.1.Cancer Applications
17.9.3.5.1.1.Lung Cancer
17.9.3.5.1.2.Breast Cancer
17.9.3.5.1.3.Colorectal Cancer
17.9.3.5.1.4.Prostate Cancer
17.9.3.5.1.5.Melanoma
17.9.3.5.1.6.Other Cancers
17.9.3.5.2.Non-cancer Applications
17.9.3.5.2.1.Non-Invasive Prenatal Testing
17.9.3.5.2.2.Organ Transplantation
17.9.3.5.2.3.Infectious Disease Testing
17.9.3.6.India Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
17.9.3.6.1.Blood Sample
17.9.3.6.2.Other Sample Types
17.9.3.7.India Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
17.9.3.7.1.Reference Laboratories
17.9.3.7.2.Hospitals and Physician Laboratories
17.9.3.7.3.Academic and Research Centers
17.9.3.7.4.Other End Users
17.9.4.New Zealand
17.9.4.1.New Zealand Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
17.9.4.1.1.Assay Kits
17.9.4.1.2.Instruments
17.9.4.1.3.Services
17.9.4.2.New Zealand Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
17.9.4.2.1.Circulating Tumor Cells
17.9.4.2.2.Circulating Tumor DNA
17.9.4.2.3.Cell-free DNA
17.9.4.2.4.Extracellular Vesicles
17.9.4.2.5.Other Circulating Biomarkers
17.9.4.3.New Zealand Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
17.9.4.3.1.Early Cancer Screening
17.9.4.3.2.Therapy Selection
17.9.4.3.3.Treatment Monitoring
17.9.4.3.4.Recurrence Monitoring
17.9.4.4.New Zealand Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
17.9.4.4.1.Multi-gene Parallel Analysis using NGS
17.9.4.4.2.Single-gene Analysis using PCR
17.9.4.5.New Zealand Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
17.9.4.5.1.Cancer Applications
17.9.4.5.1.1.Lung Cancer
17.9.4.5.1.2.Breast Cancer
17.9.4.5.1.3.Colorectal Cancer
17.9.4.5.1.4.Prostate Cancer
17.9.4.5.1.5.Melanoma
17.9.4.5.1.6.Other Cancers
17.9.4.5.2.Non-cancer Applications
17.9.4.5.2.1.Non-Invasive Prenatal Testing
17.9.4.5.2.2.Organ Transplantation
17.9.4.5.2.3.Infectious Disease Testing
17.9.4.6.New Zealand Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
17.9.4.6.1.Blood Sample
17.9.4.6.2.Other Sample Types
17.9.4.7.New Zealand Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
17.9.4.7.1.Reference Laboratories
17.9.4.7.2.Hospitals and Physician Laboratories
17.9.4.7.3.Academic and Research Centers
17.9.4.7.4.Other End Users
17.9.5.Australia
17.9.5.1.Australia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
17.9.5.1.1.Assay Kits
17.9.5.1.2.Instruments
17.9.5.1.3.Services
17.9.5.2.Australia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
17.9.5.2.1.Circulating Tumor Cells
17.9.5.2.2.Circulating Tumor DNA
17.9.5.2.3.Cell-free DNA
17.9.5.2.4.Extracellular Vesicles
17.9.5.2.5.Other Circulating Biomarkers
17.9.5.3.Australia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
17.9.5.3.1.Early Cancer Screening
17.9.5.3.2.Therapy Selection
17.9.5.3.3.Treatment Monitoring
17.9.5.3.4.Recurrence Monitoring
17.9.5.4.Australia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
17.9.5.4.1.Multi-gene Parallel Analysis using NGS
17.9.5.4.2.Single-gene Analysis using PCR
17.9.5.5.Australia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
17.9.5.5.1.Cancer Applications
17.9.5.5.1.1.Lung Cancer
17.9.5.5.1.2.Breast Cancer
17.9.5.5.1.3.Colorectal Cancer
17.9.5.5.1.4.Prostate Cancer
17.9.5.5.1.5.Melanoma
17.9.5.5.1.6.Other Cancers
17.9.5.5.2.Non-cancer Applications
17.9.5.5.2.1.Non-Invasive Prenatal Testing
17.9.5.5.2.2.Organ Transplantation
17.9.5.5.2.3.Infectious Disease Testing
17.9.5.6.Australia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
17.9.5.6.1.Blood Sample
17.9.5.6.2.Other Sample Types
17.9.5.7.Australia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
17.9.5.7.1.Reference Laboratories
17.9.5.7.2.Hospitals and Physician Laboratories
17.9.5.7.3.Academic and Research Centers
17.9.5.7.4.Other End Users
17.9.6.South Korea
17.9.6.1.South Korea Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
17.9.6.1.1.Assay Kits
17.9.6.1.2.Instruments
17.9.6.1.3.Services
17.9.6.2.South Korea Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
17.9.6.2.1.Circulating Tumor Cells
17.9.6.2.2.Circulating Tumor DNA
17.9.6.2.3.Cell-free DNA
17.9.6.2.4.Extracellular Vesicles
17.9.6.2.5.Other Circulating Biomarkers
17.9.6.3.South Korea Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
17.9.6.3.1.Early Cancer Screening
17.9.6.3.2.Therapy Selection
17.9.6.3.3.Treatment Monitoring
17.9.6.3.4.Recurrence Monitoring
17.9.6.4.South Korea Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
17.9.6.4.1.Multi-gene Parallel Analysis using NGS
17.9.6.4.2.Single-gene Analysis using PCR
17.9.6.5.South Korea Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
17.9.6.5.1.Cancer Applications
17.9.6.5.1.1.Lung Cancer
17.9.6.5.1.2.Breast Cancer
17.9.6.5.1.3.Colorectal Cancer
17.9.6.5.1.4.Prostate Cancer
17.9.6.5.1.5.Melanoma
17.9.6.5.1.6.Other Cancers
17.9.6.5.2.Non-cancer Applications
17.9.6.5.2.1.Non-Invasive Prenatal Testing
17.9.6.5.2.2.Organ Transplantation
17.9.6.5.2.3.Infectious Disease Testing
17.9.6.6.South Korea Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
17.9.6.6.1.Blood Sample
17.9.6.6.2.Other Sample Types
17.9.6.7.South Korea Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
17.9.6.7.1.Reference Laboratories
17.9.6.7.2.Hospitals and Physician Laboratories
17.9.6.7.3.Academic and Research Centers
17.9.6.7.4.Other End Users
17.9.7.Southeast Asia
17.9.7.1.Southeast Asia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
17.9.7.1.1.Assay Kits
17.9.7.1.2.Instruments
17.9.7.1.3.Services
17.9.7.2.Southeast Asia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
17.9.7.2.1.Circulating Tumor Cells
17.9.7.2.2.Circulating Tumor DNA
17.9.7.2.3.Cell-free DNA
17.9.7.2.4.Extracellular Vesicles
17.9.7.2.5.Other Circulating Biomarkers
17.9.7.3.Southeast Asia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
17.9.7.3.1.Early Cancer Screening
17.9.7.3.2.Therapy Selection
17.9.7.3.3.Treatment Monitoring
17.9.7.3.4.Recurrence Monitoring
17.9.7.4.Southeast Asia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
17.9.7.4.1.Multi-gene Parallel Analysis using NGS
17.9.7.4.2.Single-gene Analysis using PCR
17.9.7.5.Southeast Asia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
17.9.7.5.1.Cancer Applications
17.9.7.5.1.1.Lung Cancer
17.9.7.5.1.2.Breast Cancer
17.9.7.5.1.3.Colorectal Cancer
17.9.7.5.1.4.Prostate Cancer
17.9.7.5.1.5.Melanoma
17.9.7.5.1.6.Other Cancers
17.9.7.5.2.Non-cancer Applications
17.9.7.5.2.1.Non-Invasive Prenatal Testing
17.9.7.5.2.2.Organ Transplantation
17.9.7.5.2.3.Infectious Disease Testing
17.9.7.6.Southeast Asia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
17.9.7.6.1.Blood Sample
17.9.7.6.2.Other Sample Types
17.9.7.7.Southeast Asia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
17.9.7.7.1.Reference Laboratories
17.9.7.7.2.Hospitals and Physician Laboratories
17.9.7.7.3.Academic and Research Centers
17.9.7.7.4.Other End Users
17.9.7.8.Southeast Asia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Country
17.9.7.8.1.Indonesia
17.9.7.8.2.Thailand
17.9.7.8.3.Malaysia
17.9.7.8.4.Singapore
17.9.7.8.5.Rest of Southeast Asia
17.9.8.Rest of Asia Pacific
17.9.8.1.Rest of Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
17.9.8.1.1.Assay Kits
17.9.8.1.2.Instruments
17.9.8.1.3.Services
17.9.8.2.Rest of Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
17.9.8.2.1.Circulating Tumor Cells
17.9.8.2.2.Circulating Tumor DNA
17.9.8.2.3.Cell-free DNA
17.9.8.2.4.Extracellular Vesicles
17.9.8.2.5.Other Circulating Biomarkers
17.9.8.3.Rest of Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
17.9.8.3.1.Early Cancer Screening
17.9.8.3.2.Therapy Selection
17.9.8.3.3.Treatment Monitoring
17.9.8.3.4.Recurrence Monitoring
17.9.8.4.Rest of Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
17.9.8.4.1.Multi-gene Parallel Analysis using NGS
17.9.8.4.2.Single-gene Analysis using PCR
17.9.8.5.Rest of Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
17.9.8.5.1.Cancer Applications
17.9.8.5.1.1.Lung Cancer
17.9.8.5.1.2.Breast Cancer
17.9.8.5.1.3.Colorectal Cancer
17.9.8.5.1.4.Prostate Cancer
17.9.8.5.1.5.Melanoma
17.9.8.5.1.6.Other Cancers
17.9.8.5.2.Non-cancer Applications
17.9.8.5.2.1.Non-Invasive Prenatal Testing
17.9.8.5.2.2.Organ Transplantation
17.9.8.5.2.3.Infectious Disease Testing
17.9.8.6.Rest of Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
17.9.8.6.1.Blood Sample
17.9.8.6.2.Other Sample Types
17.9.8.7.Rest of Asia Pacific Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
17.9.8.7.1.Reference Laboratories
17.9.8.7.2.Hospitals and Physician Laboratories
17.9.8.7.3.Academic and Research Centers
17.9.8.7.4.Other End Users
17.10.Key Segment for Channeling Investments
17.10.1.By Country
17.10.2.By Product and Service
17.10.3.By Circulating Biomarker
17.10.4.By Clinical Application
17.10.5.By Technology
17.10.6.By Application
17.10.7.By Sample Type
17.10.8.By End User
18.Middle East and Africa Liquid Biopsy Market Analysis and Forecasts, 2024 – 2034
18.1.Overview
18.1.1.Middle East and Africa Liquid Biopsy Market Revenue (US$ Mn)
18.2.Middle East and Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
18.2.1.Assay Kits
18.2.2.Instruments
18.2.3.Services
18.3.Middle East and Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
18.3.1.Circulating Tumor Cells
18.3.2.Circulating Tumor DNA
18.3.3.Cell-free DNA
18.3.4.Extracellular Vesicles
18.3.5.Other Circulating Biomarkers
18.4.Middle East and Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
18.4.1.Early Cancer Screening
18.4.2.Therapy Selection
18.4.3.Treatment Monitoring
18.4.4.Recurrence Monitoring
18.5.Middle East and Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
18.5.1.Multi-gene Parallel Analysis using NGS
18.5.2.Single-gene Analysis using PCR
18.6.Middle East and Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
18.6.1.Cancer Applications
18.6.1.1.Lung Cancer
18.6.1.2.Breast Cancer
18.6.1.3.Colorectal Cancer
18.6.1.4.Prostate Cancer
18.6.1.5.Melanoma
18.6.1.6.Other Cancers
18.6.2.Non-cancer Applications
18.6.2.1.Non-Invasive Prenatal Testing
18.6.2.2.Organ Transplantation
18.6.2.3.Infectious Disease Testing
18.7.Middle East and Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
18.7.1.Blood Sample
18.7.2.Other Sample Types
18.8.Middle East and Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
18.8.1.Reference Laboratories
18.8.2.Hospitals and Physician Laboratories
18.8.3.Academic and Research Centers
18.8.4.Other End Users
18.9.Middle East and Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Country
18.9.1.Saudi Arabia
18.9.1.1.Saudi Arabia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
18.9.1.1.1.Assay Kits
18.9.1.1.2.Instruments
18.9.1.1.3.Services
18.9.1.2.Saudi Arabia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
18.9.1.2.1.Circulating Tumor Cells
18.9.1.2.2.Circulating Tumor DNA
18.9.1.2.3.Cell-free DNA
18.9.1.2.4.Extracellular Vesicles
18.9.1.2.5.Other Circulating Biomarkers
18.9.1.3.Saudi Arabia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
18.9.1.3.1.Early Cancer Screening
18.9.1.3.2.Therapy Selection
18.9.1.3.3.Treatment Monitoring
18.9.1.3.4.Recurrence Monitoring
18.9.1.4.Saudi Arabia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
18.9.1.4.1.Multi-gene Parallel Analysis using NGS
18.9.1.4.2.Single-gene Analysis using PCR
18.9.1.5.Saudi Arabia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
18.9.1.5.1.Cancer Applications
18.9.1.5.1.1.Lung Cancer
18.9.1.5.1.2.Breast Cancer
18.9.1.5.1.3.Colorectal Cancer
18.9.1.5.1.4.Prostate Cancer
18.9.1.5.1.5.Melanoma
18.9.1.5.1.6.Other Cancers
18.9.1.5.2.Non-cancer Applications
18.9.1.5.2.1.Non-Invasive Prenatal Testing
18.9.1.5.2.2.Organ Transplantation
18.9.1.5.2.3.Infectious Disease Testing
18.9.1.6.Saudi Arabia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
18.9.1.6.1.Blood Sample
18.9.1.6.2.Other Sample Types
18.9.1.7.Saudi Arabia Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
18.9.1.7.1.Reference Laboratories
18.9.1.7.2.Hospitals and Physician Laboratories
18.9.1.7.3.Academic and Research Centers
18.9.1.7.4.Other End Users
18.9.2.UAE
18.9.2.1.UAE Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
18.9.2.1.1.Assay Kits
18.9.2.1.2.Instruments
18.9.2.1.3.Services
18.9.2.2.UAE Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
18.9.2.2.1.Circulating Tumor Cells
18.9.2.2.2.Circulating Tumor DNA
18.9.2.2.3.Cell-free DNA
18.9.2.2.4.Extracellular Vesicles
18.9.2.2.5.Other Circulating Biomarkers
18.9.2.3.UAE Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
18.9.2.3.1.Early Cancer Screening
18.9.2.3.2.Therapy Selection
18.9.2.3.3.Treatment Monitoring
18.9.2.3.4.Recurrence Monitoring
18.9.2.4.UAE Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
18.9.2.4.1.Multi-gene Parallel Analysis using NGS
18.9.2.4.2.Single-gene Analysis using PCR
18.9.2.5.UAE Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
18.9.2.5.1.Cancer Applications
18.9.2.5.1.1.Lung Cancer
18.9.2.5.1.2.Breast Cancer
18.9.2.5.1.3.Colorectal Cancer
18.9.2.5.1.4.Prostate Cancer
18.9.2.5.1.5.Melanoma
18.9.2.5.1.6.Other Cancers
18.9.2.5.2.Non-cancer Applications
18.9.2.5.2.1.Non-Invasive Prenatal Testing
18.9.2.5.2.2.Organ Transplantation
18.9.2.5.2.3.Infectious Disease Testing
18.9.2.6.UAE Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
18.9.2.6.1.Blood Sample
18.9.2.6.2.Other Sample Types
18.9.2.7.UAE Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
18.9.2.7.1.Reference Laboratories
18.9.2.7.2.Hospitals and Physician Laboratories
18.9.2.7.3.Academic and Research Centers
18.9.2.7.4.Other End Users
18.9.3.Egypt
18.9.3.1.Egypt Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
18.9.3.1.1.Assay Kits
18.9.3.1.2.Instruments
18.9.3.1.3.Services
18.9.3.2.Egypt Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
18.9.3.2.1.Circulating Tumor Cells
18.9.3.2.2.Circulating Tumor DNA
18.9.3.2.3.Cell-free DNA
18.9.3.2.4.Extracellular Vesicles
18.9.3.2.5.Other Circulating Biomarkers
18.9.3.3.Egypt Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
18.9.3.3.1.Early Cancer Screening
18.9.3.3.2.Therapy Selection
18.9.3.3.3.Treatment Monitoring
18.9.3.3.4.Recurrence Monitoring
18.9.3.4.Egypt Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
18.9.3.4.1.Multi-gene Parallel Analysis using NGS
18.9.3.4.2.Single-gene Analysis using PCR
18.9.3.5.Egypt Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
18.9.3.5.1.Cancer Applications
18.9.3.5.1.1.Lung Cancer
18.9.3.5.1.2.Breast Cancer
18.9.3.5.1.3.Colorectal Cancer
18.9.3.5.1.4.Prostate Cancer
18.9.3.5.1.5.Melanoma
18.9.3.5.1.6.Other Cancers
18.9.3.5.2.Non-cancer Applications
18.9.3.5.2.1.Non-Invasive Prenatal Testing
18.9.3.5.2.2.Organ Transplantation
18.9.3.5.2.3.Infectious Disease Testing
18.9.3.6.Egypt Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
18.9.3.6.1.Blood Sample
18.9.3.6.2.Other Sample Types
18.9.3.7.Egypt Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
18.9.3.7.1.Reference Laboratories
18.9.3.7.2.Hospitals and Physician Laboratories
18.9.3.7.3.Academic and Research Centers
18.9.3.7.4.Other End Users
18.9.4.Kuwait
18.9.4.1.Kuwait Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
18.9.4.1.1.Assay Kits
18.9.4.1.2.Instruments
18.9.4.1.3.Services
18.9.4.2.Kuwait Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
18.9.4.2.1.Circulating Tumor Cells
18.9.4.2.2.Circulating Tumor DNA
18.9.4.2.3.Cell-free DNA
18.9.4.2.4.Extracellular Vesicles
18.9.4.2.5.Other Circulating Biomarkers
18.9.4.3.Kuwait Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
18.9.4.3.1.Early Cancer Screening
18.9.4.3.2.Therapy Selection
18.9.4.3.3.Treatment Monitoring
18.9.4.3.4.Recurrence Monitoring
18.9.4.4.Kuwait Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
18.9.4.4.1.Multi-gene Parallel Analysis using NGS
18.9.4.4.2.Single-gene Analysis using PCR
18.9.4.5.Kuwait Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
18.9.4.5.1.Cancer Applications
18.9.4.5.1.1.Lung Cancer
18.9.4.5.1.2.Breast Cancer
18.9.4.5.1.3.Colorectal Cancer
18.9.4.5.1.4.Prostate Cancer
18.9.4.5.1.5.Melanoma
18.9.4.5.1.6.Other Cancers
18.9.4.5.2.Non-cancer Applications
18.9.4.5.2.1.Non-Invasive Prenatal Testing
18.9.4.5.2.2.Organ Transplantation
18.9.4.5.2.3.Infectious Disease Testing
18.9.4.6.Kuwait Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
18.9.4.6.1.Blood Sample
18.9.4.6.2.Other Sample Types
18.9.4.7.Kuwait Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
18.9.4.7.1.Reference Laboratories
18.9.4.7.2.Hospitals and Physician Laboratories
18.9.4.7.3.Academic and Research Centers
18.9.4.7.4.Other End Users
18.9.5.South Africa
18.9.5.1.South Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
18.9.5.1.1.Assay Kits
18.9.5.1.2.Instruments
18.9.5.1.3.Services
18.9.5.2.South Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
18.9.5.2.1.Circulating Tumor Cells
18.9.5.2.2.Circulating Tumor DNA
18.9.5.2.3.Cell-free DNA
18.9.5.2.4.Extracellular Vesicles
18.9.5.2.5.Other Circulating Biomarkers
18.9.5.3.South Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
18.9.5.3.1.Early Cancer Screening
18.9.5.3.2.Therapy Selection
18.9.5.3.3.Treatment Monitoring
18.9.5.3.4.Recurrence Monitoring
18.9.5.4.South Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
18.9.5.4.1.Multi-gene Parallel Analysis using NGS
18.9.5.4.2.Single-gene Analysis using PCR
18.9.5.5.South Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
18.9.5.5.1.Cancer Applications
18.9.5.5.1.1.Lung Cancer
18.9.5.5.1.2.Breast Cancer
18.9.5.5.1.3.Colorectal Cancer
18.9.5.5.1.4.Prostate Cancer
18.9.5.5.1.5.Melanoma
18.9.5.5.1.6.Other Cancers
18.9.5.5.2.Non-cancer Applications
18.9.5.5.2.1.Non-Invasive Prenatal Testing
18.9.5.5.2.2.Organ Transplantation
18.9.5.5.2.3.Infectious Disease Testing
18.9.5.6.South Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
18.9.5.6.1.Blood Sample
18.9.5.6.2.Other Sample Types
18.9.5.7.South Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
18.9.5.7.1.Reference Laboratories
18.9.5.7.2.Hospitals and Physician Laboratories
18.9.5.7.3.Academic and Research Centers
18.9.5.7.4.Other End Users
18.9.6.Rest of Middle East & Africa
18.9.6.1.Rest of Middle East & Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
18.9.6.1.1.Assay Kits
18.9.6.1.2.Instruments
18.9.6.1.3.Services
18.9.6.2.Rest of Middle East & Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
18.9.6.2.1.Circulating Tumor Cells
18.9.6.2.2.Circulating Tumor DNA
18.9.6.2.3.Cell-free DNA
18.9.6.2.4.Extracellular Vesicles
18.9.6.2.5.Other Circulating Biomarkers
18.9.6.3.Rest of Middle East & Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
18.9.6.3.1.Early Cancer Screening
18.9.6.3.2.Therapy Selection
18.9.6.3.3.Treatment Monitoring
18.9.6.3.4.Recurrence Monitoring
18.9.6.4.Rest of Middle East & Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
18.9.6.4.1.Multi-gene Parallel Analysis using NGS
18.9.6.4.2.Single-gene Analysis using PCR
18.9.6.5.Rest of Middle East & Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
18.9.6.5.1.Cancer Applications
18.9.6.5.1.1.Lung Cancer
18.9.6.5.1.2.Breast Cancer
18.9.6.5.1.3.Colorectal Cancer
18.9.6.5.1.4.Prostate Cancer
18.9.6.5.1.5.Melanoma
18.9.6.5.1.6.Other Cancers
18.9.6.5.2.Non-cancer Applications
18.9.6.5.2.1.Non-Invasive Prenatal Testing
18.9.6.5.2.2.Organ Transplantation
18.9.6.5.2.3.Infectious Disease Testing
18.9.6.6.Rest of Middle East & Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
18.9.6.6.1.Blood Sample
18.9.6.6.2.Other Sample Types
18.9.6.7.Rest of Middle East & Africa Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
18.9.6.7.1.Reference Laboratories
18.9.6.7.2.Hospitals and Physician Laboratories
18.9.6.7.3.Academic and Research Centers
18.9.6.7.4.Other End Users
18.10.Key Segment for Channeling Investments
18.10.1.By Country
18.10.2.By Product and Service
18.10.3.By Circulating Biomarker
18.10.4.By Clinical Application
18.10.5.By Technology
18.10.6.By Application
18.10.7.By Sample Type
18.10.8.By End User
19.Latin America Liquid Biopsy Market Analysis and Forecasts, 2024 – 2034
19.1.Overview
19.1.1.Latin America Liquid Biopsy Market Revenue (US$ Mn)
19.2.Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
19.2.1.Assay Kits
19.2.2.Instruments
19.2.3.Services
19.3.Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
19.3.1.Circulating Tumor Cells
19.3.2.Circulating Tumor DNA
19.3.3.Cell-free DNA
19.3.4.Extracellular Vesicles
19.3.5.Other Circulating Biomarkers
19.4.Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
19.4.1.Early Cancer Screening
19.4.2.Therapy Selection
19.4.3.Treatment Monitoring
19.4.4.Recurrence Monitoring
19.5.Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
19.5.1.Multi-gene Parallel Analysis using NGS
19.5.2.Single-gene Analysis using PCR
19.6.Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
19.6.1.Cancer Applications
19.6.1.1.Lung Cancer
19.6.1.2.Breast Cancer
19.6.1.3.Colorectal Cancer
19.6.1.4.Prostate Cancer
19.6.1.5.Melanoma
19.6.1.6.Other Cancers
19.6.2.Non-cancer Applications
19.6.2.1.Non-Invasive Prenatal Testing
19.6.2.2.Organ Transplantation
19.6.2.3.Infectious Disease Testing
19.7.Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
19.7.1.Blood Sample
19.7.2.Other Sample Types
19.8.Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
19.8.1.Reference Laboratories
19.8.2.Hospitals and Physician Laboratories
19.8.3.Academic and Research Centers
19.8.4.Other End Users
19.9.Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Country
19.9.1.Brazil
19.9.1.1.Brazil Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
19.9.1.1.1.Assay Kits
19.9.1.1.2.Instruments
19.9.1.1.3.Services
19.9.1.2.Brazil Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
19.9.1.2.1.Circulating Tumor Cells
19.9.1.2.2.Circulating Tumor DNA
19.9.1.2.3.Cell-free DNA
19.9.1.2.4.Extracellular Vesicles
19.9.1.2.5.Other Circulating Biomarkers
19.9.1.3.Brazil Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
19.9.1.3.1.Early Cancer Screening
19.9.1.3.2.Therapy Selection
19.9.1.3.3.Treatment Monitoring
19.9.1.3.4.Recurrence Monitoring
19.9.1.4.Brazil Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
19.9.1.4.1.Multi-gene Parallel Analysis using NGS
19.9.1.4.2.Single-gene Analysis using PCR
19.9.1.5.Brazil Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
19.9.1.5.1.Cancer Applications
19.9.1.5.1.1.Lung Cancer
19.9.1.5.1.2.Breast Cancer
19.9.1.5.1.3.Colorectal Cancer
19.9.1.5.1.4.Prostate Cancer
19.9.1.5.1.5.Melanoma
19.9.1.5.1.6.Other Cancers
19.9.1.5.2.Non-cancer Applications
19.9.1.5.2.1.Non-Invasive Prenatal Testing
19.9.1.5.2.2.Organ Transplantation
19.9.1.5.2.3.Infectious Disease Testing
19.9.1.6.Brazil Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
19.9.1.6.1.Blood Sample
19.9.1.6.2.Other Sample Types
19.9.1.7.Brazil Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
19.9.1.7.1.Reference Laboratories
19.9.1.7.2.Hospitals and Physician Laboratories
19.9.1.7.3.Academic and Research Centers
19.9.1.7.4.Other End Users
19.9.2.Argentina
19.9.2.1.Argentina Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
19.9.2.1.1.Assay Kits
19.9.2.1.2.Instruments
19.9.2.1.3.Services
19.9.2.2.Argentina Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
19.9.2.2.1.Circulating Tumor Cells
19.9.2.2.2.Circulating Tumor DNA
19.9.2.2.3.Cell-free DNA
19.9.2.2.4.Extracellular Vesicles
19.9.2.2.5.Other Circulating Biomarkers
19.9.2.3.Argentina Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
19.9.2.3.1.Early Cancer Screening
19.9.2.3.2.Therapy Selection
19.9.2.3.3.Treatment Monitoring
19.9.2.3.4.Recurrence Monitoring
19.9.2.4.Argentina Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
19.9.2.4.1.Multi-gene Parallel Analysis using NGS
19.9.2.4.2.Single-gene Analysis using PCR
19.9.2.5.Argentina Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
19.9.2.5.1.Cancer Applications
19.9.2.5.1.1.Lung Cancer
19.9.2.5.1.2.Breast Cancer
19.9.2.5.1.3.Colorectal Cancer
19.9.2.5.1.4.Prostate Cancer
19.9.2.5.1.5.Melanoma
19.9.2.5.1.6.Other Cancers
19.9.2.5.2.Non-cancer Applications
19.9.2.5.2.1.Non-Invasive Prenatal Testing
19.9.2.5.2.2.Organ Transplantation
19.9.2.5.2.3.Infectious Disease Testing
19.9.2.6.Argentina Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
19.9.2.6.1.Blood Sample
19.9.2.6.2.Other Sample Types
19.9.2.7.Argentina Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
19.9.2.7.1.Reference Laboratories
19.9.2.7.2.Hospitals and Physician Laboratories
19.9.2.7.3.Academic and Research Centers
19.9.2.7.4.Other End Users
19.9.3.Rest of Latin America
19.9.3.1.Rest of Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Product and Service
19.9.3.1.1.Assay Kits
19.9.3.1.2.Instruments
19.9.3.1.3.Services
19.9.3.2.Rest of Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Circulating Biomarker
19.9.3.2.1.Circulating Tumor Cells
19.9.3.2.2.Circulating Tumor DNA
19.9.3.2.3.Cell-free DNA
19.9.3.2.4.Extracellular Vesicles
19.9.3.2.5.Other Circulating Biomarkers
19.9.3.3.Rest of Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Clinical Application
19.9.3.3.1.Early Cancer Screening
19.9.3.3.2.Therapy Selection
19.9.3.3.3.Treatment Monitoring
19.9.3.3.4.Recurrence Monitoring
19.9.3.4.Rest of Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Technology
19.9.3.4.1.Multi-gene Parallel Analysis using NGS
19.9.3.4.2.Single-gene Analysis using PCR
19.9.3.5.Rest of Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Application
19.9.3.5.1.Cancer Applications
19.9.3.5.1.1.Lung Cancer
19.9.3.5.1.2.Breast Cancer
19.9.3.5.1.3.Colorectal Cancer
19.9.3.5.1.4.Prostate Cancer
19.9.3.5.1.5.Melanoma
19.9.3.5.1.6.Other Cancers
19.9.3.5.2.Non-cancer Applications
19.9.3.5.2.1.Non-Invasive Prenatal Testing
19.9.3.5.2.2.Organ Transplantation
19.9.3.5.2.3.Infectious Disease Testing
19.9.3.6.Rest of Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By Sample Type
19.9.3.6.1.Blood Sample
19.9.3.6.2.Other Sample Types
19.9.3.7.Rest of Latin America Liquid Biopsy Market Revenue (US$ Mn) and Forecasts, By End User
19.9.3.7.1.Reference Laboratories
19.9.3.7.2.Hospitals and Physician Laboratories
19.9.3.7.3.Academic and Research Centers
19.9.3.7.4.Other End Users
19.10.Key Segment for Channeling Investments
19.10.1.By Country
19.10.2.By Product and Service
19.10.3.By Circulating Biomarker
19.10.4.By Clinical Application
19.10.5.By Technology
19.10.6.By Application
19.10.7.By Sample Type
19.10.8.By End User
20.Competitive Benchmarking
20.1.Brand Benchmarking
20.2.Market Share Analysis, 2023
20.3.Global Presence and Growth Strategies
20.3.1.Mergers and Acquisitions
20.3.2.Product Launches
20.3.3.Investments Trends
20.3.4.R&D Initiatives
21.Player Profiles
21.1.Biocept Inc.
21.1.1.Company Details
21.1.2.Company Overview
21.1.3.Product Offerings
21.1.4.Key Developments
21.1.5.Financial Analysis
21.1.6.SWOT Analysis
21.1.7.Business Strategies
21.2.Bio-Rad Laboratories
21.2.1.Company Details
21.2.2.Company Overview
21.2.3.Product Offerings
21.2.4.Key Developments
21.2.5.Financial Analysis
21.2.6.SWOT Analysis
21.2.7.Business Strategies
21.3.F. Hoffmann-La Roche Ltd.
21.3.1.Company Details
21.3.2.Company Overview
21.3.3.Product Offerings
21.3.4.Key Developments
21.3.5.Financial Analysis
21.3.6.SWOT Analysis
21.3.7.Business Strategies
21.4.Guardant Health
21.4.1.Company Details
21.4.2.Company Overview
21.4.3.Product Offerings
21.4.4.Key Developments
21.4.5.Financial Analysis
21.4.6.SWOT Analysis
21.4.7.Business Strategies
21.5.Illumina, Inc.
21.5.1.Company Details
21.5.2.Company Overview
21.5.3.Product Offerings
21.5.4.Key Developments
21.5.5.Financial Analysis
21.5.6.SWOT Analysis
21.5.7.Business Strategies
21.6.Johnson and Johnson
21.6.1.Company Details
21.6.2.Company Overview
21.6.3.Product Offerings
21.6.4.Key Developments
21.6.5.Financial Analysis
21.6.6.SWOT Analysis
21.6.7.Business Strategies
21.7.Laboratory Corporation of America Holdings
21.7.1.Company Details
21.7.2.Company Overview
21.7.3.Product Offerings
21.7.4.Key Developments
21.7.5.Financial Analysis
21.7.6.SWOT Analysis
21.7.7.Business Strategies
21.8.MDxHealth SA
21.8.1.Company Details
21.8.2.Company Overview
21.8.3.Product Offerings
21.8.4.Key Developments
21.8.5.Financial Analysis
21.8.6.SWOT Analysis
21.8.7.Business Strategies
21.9.QIAGEN N.V
21.9.1.Company Details
21.9.2.Company Overview
21.9.3.Product Offerings
21.9.4.Key Developments
21.9.5.Financial Analysis
21.9.6.SWOT Analysis
21.9.7.Business Strategies
21.10.Thermo Fisher Scientific Inc.
21.10.1.Company Details
21.10.2.Company Overview
21.10.3.Product Offerings
21.10.4.Key Developments
21.10.5.Financial Analysis
21.10.6.SWOT Analysis
21.10.7.Business Strategies
21.11.Other Industry Participants
22.Key Findings

.

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

.

**Exclusive for Multi-User and Enterprise User.

Global Liquid Biopsy Market

By Product & Service

  • Assay Kits
  • Instruments
  • Services

By Circulating Biomarker

  • Circulating Tumor Cells
  • Circulating Tumor DNA
  • Cell-free DNA
  • Extracellular Vesicles
  • Other Circulating Biomarkers

By Clinical Application

  • Early Cancer Screening
  • Therapy Selection
  • Treatment Monitoring
  • Recurrence Monitoring

By Technology

  • Multi-gene Parallel Analysis using NGS
  • Single-gene Analysis using PCR

By Application

  • Cancer Applications
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Melanoma
    • Other Cancers
  • Non-cancer Applications
    • Non-Invasive Prenatal Testing
    • Organ Transplantation
    • Infectious Disease Testing

By Sample Type

  • Blood Sample
  • Other Sample Types

By End User

  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Academic & Research Centers
  • Other End Users

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

The Niche Research approach encompasses both primary and secondary research methods to provide comprehensive insights. While primary research is the cornerstone of our studies, we also incorporate secondary research sources such as company annual reports, premium industry databases, press releases, industry journals, and white papers.

Within our primary research, we actively engage with various industry stakeholders, conducting paid interviews and surveys. Our meticulous analysis extends to every market participant in major countries, allowing us to thoroughly examine their portfolios, calculate market shares, and segment revenues.

Our data collection primarily focuses on individual countries within our research scope, enabling us to estimate regional market sizes. Typically, we employ a bottom-up approach, meticulously tracking trends in different countries. We analyze growth drivers, constraints, technological innovations, and opportunities for each country, ultimately arriving at regional figures.Our process begins by examining the growth prospects of each country. Building upon these insights, we project growth and trends for the entire region. Finally, we utilize our proprietary model to refine estimations and forecasts.

Our data validation standards are integral to ensuring the reliability and accuracy of our research findings. Here’s a breakdown of our data validation processes and the stakeholders we engage with during our primary research:

  • Supply Side Analysis: We initiate a supply side analysis by directly contacting market participants, through telephonic interviews and questionnaires containing both open-ended and close-ended questions. We gather information on their portfolios, segment revenues, developments, and growth strategies.
  • Demand Side Analysis: To gain insights into adoption trends and consumer preferences, we reach out to target customers and users (non-vendors). This information forms a vital part of the qualitative analysis section of our reports, covering market dynamics, adoption trends, consumer behavior, spending patterns, and other related aspects.
  • Consultant Insights: We tap into the expertise of our partner consultants from around the world to obtain their unique viewpoints and perspectives. Their insights contribute to a well-rounded understanding of the markets under investigation.
  • In-House Validation: To ensure data accuracy and reliability, we conduct cross-validation of data points and information through our in-house team of consultants and utilize advanced data modeling tools for thorough verification.

The forecasts we provide are based on a comprehensive assessment of various factors, including:

  • Market Trends and Past Performance (Last Five Years): We accurately analyze market trends and performance data from preceding five years to identify historical patterns and understand the market’s evolution.
  • Historical Performance and Growth of Market Participants: We assess the historical performance and growth trajectories of key market participants. This analysis provides insights into the competitive landscape and individual company strategies.
  • Market Determinants Impact Analysis (Next Eight Years): We conduct a rigorous analysis of the factors that are projected to influence the market over the next eight years. This includes assessing both internal and external determinants that can shape market dynamics.
  • Drivers and Challenges for the Forecast Period:Identify the factors expected to drive market growth during the forecast period, as well as the challenges that the industry may face. This analysis aids in deriving an accurate growth rate projection.
  • New Acquisitions, Collaborations, or Partnerships: We keep a close watch on any new acquisitions, collaborations, or partnerships within the industry. These developments can have a significant impact on market dynamics and competitiveness.
  • Macro and Micro Factors Analysis:A thorough examination of both macro-level factors (e.g., economic trends, regulatory changes) and micro-level factors (e.g., technological advancements, consumer preferences) that may influence the market during the forecast period.
  • End-User Sentiment Analysis: To understand the market from the end-user perspective, we conduct sentiment analysis. This involves assessing the sentiment, preferences, and feedback of the end-users, which can provide valuable insights into market trends.
  • Perspective of Primary Participants: Insights gathered directly from primary research participants play a crucial role in shaping our forecasts. Their perspectives and experiences provide valuable qualitative data.
  • Year-on-Year Growth Trend: We utilize a year-on-year growth trend based on historical market growth and expected future trends. This helps in formulating our growth projections, aligning them with the market’s historical performance.

Research process adopted by TNR involves multiple stages, including data collection, validation, quality checks, and presentation. It’s crucial that the data and information we provide add value to your existing market understanding and expertise. We have also established partnerships with business consulting, research, and survey organizations across regions and globally to collaborate on regional analysis and data validation, ensuring the highest level of accuracy and reliability in our reports.

 

 

Procure Comprehensive Study of

Global Liquid Biopsy Market

Online Only

  • Online Access
  • Read Only File
  • Validity 3 Months
  • Print, Copy, Paste & Download
  • PPT, Excel
  • Cost-Free Report in the Next Update
$3300
Buy Now

Single User

  • Access to One User on One System
  • Read Only File
  • Validity 6 Months
  • Limited Print,Copy, Paste
  • PPT, Excel
  • Cost-Free Report in the Next Update
$4200
Buy Now

Multi User

  • Access to Fiver Users
  • PDF File
  • Validity 1 Year
  • Upto FivePrints
  • Cost-Free Report in the Next Update
  • PPT, Excel
$6000
Buy Now

Enterprise User

  • Access to Unlimited Users
  • PDF, PPT, Excel
  • Unlimited Validity, Prints&Downloads
  • 1 Hour Cost-Free & Dedicated Analyst Support
  • 10% Cost-Free Customization
  • Cost-Free Report Update Twice in a Year
  • Recommendations for Business Strategies
  • Authorization to Quote TNR, The Niche Research
$7300
Buy Now

Library Access

  • Online Access to Content Publications
  • Access Player Profiles Online
  • Get Immediate Access to Newly Added Content
  • Acquire 12 PDF Downloads
  • Acquire 5 Excel Data Sets
  • Gain Access to 290+ PDFs of Company Profiles
  • Round-the-clock Email and Phone Assistance
  • Dashboard Usage and Trends
  • Renewal & Upgrade Assistance
  • Assessing Customization Options and Alerts for New Reports
$10788
Buy Now
*Taxes/Fees, if applicable will be added during checkout. All prices in USD

Why TNR The Niche Research?

  • Unwavering Commitment to Excellence

  • Veteran Team of Researchers

  • Accurate and Timely Insights

  • Ethical Practices and Customized Service

  • Uninterrupted Availability Around the Clock

Scroll to Top